Background
==========

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia in the general population and is associated with a high risk of developing morbidities such as hemodynamic instability, thromboembolism, stroke, hospital re-admissions, and increasing health care costs \[[@b1-medscimonitbasicres-23-97]\]. AF alone is associated with a 1.5% to 1.9% increase in risk of mortality in both sexes across a wide range of ages \[[@b2-medscimonitbasicres-23-97]\]. Moreover, the situation is likely to worsen since the number of people with AF is expected to double by 2050 \[[@b2-medscimonitbasicres-23-97]\], AF is linked to a 5-fold increased risk of cerebrovascular events, and approximately 20% of strokes are related to AF \[[@b3-medscimonitbasicres-23-97]\].

Recently, researchers have suggested several important mechanisms for the occurrence of AF, including oxidative stress reactions and systemic inflammation \[[@b4-medscimonitbasicres-23-97]\]. The pathophysiological mechanism associated with the higher prothrombotic tendency in AF is highly complex and multifactorial \[[@b5-medscimonitbasicres-23-97]\]. Virchow's triad regarding prothrombotic state, including changed blood flow (arterial stasis), abnormalities in vessel wall, and coagulant alternations in the hemostatic balance, may play an important role in the occurrence of supraventricular arrhythmia \[[@b6-medscimonitbasicres-23-97]\].

Various studies have reported the association of hemostatic markers with the occurrence of AF. However, so far, the data from these studies are largely inconclusive. The present systematic review with meta-analysis sought to determine the strength of evidence for evaluating the role of coagulation activation, fibrinolytic, and endothelial function in the occurrence of AF and related consequent outcomes such as thromboembolism and stroke.

Material and Methods
====================

Literature search
-----------------

A systematic and comprehensive literature search was conducted in electronic databases (Medline/PubMed, Embase, Web of Science, and Google Scholar) from their inception through 5 August 2016 to identify relevant studies on the association of coagulation, fibrinolytic, and endothelial functional assessment with the occurrence of AF and related consequent clinical adverse events, including thromboembolism and stroke. Predefined search terms were: coagulation \["fibrinogen", "D-dimer", "prothrombin fragment 1--2", "antithrombin III", "thrombin-antithrombin"\], fibrinolytic \["tissue-type plasminogen activator", "plasminogen activator inhibitor", "alfa-2 antiplasmin", "fibrinopeptide-A", "urokinase-type plasminogen activator", "plasmin-antiplasmin"\], endothelial function \["von Willebrand factor", "soluble thrombomodulin"\], and "atrial fibrillation". No limitations were imposed on language, time of publication, or sample size of studies. All retrieved references of the included studies and recent published review articles and meta-analyses were also reviewed to determine additional studies not indexed in major databases.

Study selection
---------------

Studies were included in the analysis when they met the following criteria: 1) human subjects; 2) case-control or cohort studies; 3) the study investigated the comparison between AF-cases and non-AF-population regarding biomarkers of endothelial, coagulation, and fibrinolytic function; 4) the study compared cohorts of patients with and without stroke, as well as with and without thromboembolic events in patients with AF in terms of biomarkers. Abstracts without peer-review, abstracts from congress presentations, and gray literature were not included.

Data extraction and outcome measures
------------------------------------

Three investigators (S.A.-H-S, A.W., and A.S.) extracted the data independently, and discrepancies were resolved via a consensus standardized abstraction checklist used for recording data in each enrolled study. Disagreements were resolved through discussion with senior authors (A.F.-P, G.B.Z, and H.C.). Author's name, year of publication, country, design of study, procedure, sample size, mean age, sex, coexistent cardiovascular disease and risk factors, anticoagulants, type of AF, and details of hemostatic markers were extracted. For exploration of heterogeneity among trials, subgroup analyses of disparities in the patients' characteristics were performed for (1) year of publication (before 2000 *vs.* after 2000); (2) geographic area (Asia, Europe, Africa, North-America, South-America, and Oceania); (3) design of the study (case-control *vs.* cohort); (4) number of patients (≤300 *vs.* \>300); (5) mean age (≤60 years *vs.* \>60 years); (6) percentage of males (≤70% *vs.* \>70%); (7) diabetes (≤30% *vs.* \>30%); (8) hypertension (≤70% *vs.* \>70%); (9) myocardial infarction (≤20% *vs.* \>20%); (10) AF-classification (acute and sub-acute *vs.* chronic); (11) type of AF (paroxysmal, persistent, permanent); and (12) anticoagulation (code-1: no patient received anticoagulants in both groups, code-2: all participants were anticoagulated in both groups, code-3: range of percentages between both groups more than 50%, code-4: range of percentages between both groups less than 50%, code-5: anticoagulation information was not available in both groups, and code-6: anticoagulation information was not available in 1 group only).

Homogenization of extracted data
--------------------------------

The suitable form of data for analyzing was mean ± standard deviation (SD). For studies that reported interquartile ranges instead of the range, we estimated means according to \[minimum+maximum+2(median)\]/4 and SD according to (maximum-minimum)/4 for groups with sample sizes up to about 70 and (maximum-minimum)/6 for sample sizes more than 70 \[[@b7-medscimonitbasicres-23-97]\].

Quality assessment and statistical analysis
-------------------------------------------

Two investigators (L.M. and M.G.) independently assessed the quality of studies by using the Newcastle-Ottawa scale \[[@b8-medscimonitbasicres-23-97]\]. The total scores ranged from 0 (worst quality) to 9 (best quality) for case-control or cohort studies. Data were analyzed by STATA software version 11.0 utilizing METAN and METABIAS modules. The pooled effect size measured was weighted mean difference (WMD) with 95% CI for non-categorical data. Heterogeneity *p* value \<0.1 for Q test or I^2^ \>50% indicated significant heterogeneity among the studies. Heterogeneity among trials was accounted for by applying a random effect model when indicated. Sample weighting assigned studies with larger sample sizes and more weight, and reduced the effect of sampling error because sampling error generally decreases as the sample size increases. The presence of publication bias was evaluated using the Begg tests. Results were considered statistically significant at a *P* value \<0.05.

Results
=======

Literature search strategy and included studies
-----------------------------------------------

The literature search retrieved 1703 studies from screened databases, of which 1527 (89.6%) were excluded after detailed evaluation in the initial review due to either redundant information (n=1095), insufficient reporting of endpoints of interest (*n*=398), or reporting of non-matched data according to mean ± SD or median \[minimum-maximum\] (*n*=34); 176 potentially relevant full-text articles were reviewed, and a total of 71 studies were finally included in the meta-analysis ([Supplementary Table 1](#s24-medscimonitbasicres-23-97){ref-type="supplementary-material"}).

Association of coagulation markers with AF
------------------------------------------

### D-dimer

A total of 7954 cases were included from 41 studies. Patient populations in the included studies ranged from 22 to 3120 patients. Of 7954 cases, 2269 were allocated to AF group and 5685 to the SR group. Mean D-dimer levels were 520.05 μg/mL in AF group and 249.28 μg/mL in SR group (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled assessment effect analysis revealed that the mean D-dimer level was significantly higher in patients with AF than in patients with SR with WMD of 197.67 (95% CI: 172.96--222.38; p\<0.001, [Figure 1](#f1-medscimonitbasicres-23-97){ref-type="fig"}) using a random effect model. Significant heterogeneity was observed among the studies (I^2^=99.8%; heterogeneity p\<0.001).

### Fibrinogen

A total of 43174 cases were included from 58 studies. Patient populations of the included studies ranged from 22 to 11 107 patients. Of 43 174 cases, 5583 were allocated to AF group and 37 591 to the SR group. Mean level of fibrinogen was 3.24 g/L in the AF group and 2.78 g/L in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled analysis showed that fibrinogen level was significantly higher in patients with AF compared to those with SR with WMD of 0.43 (95% CI: 0.36--0.51; p\<0.001, [Figure 2](#f2-medscimonitbasicres-23-97){ref-type="fig"}) using a random effect model. There was significant heterogeneity among the studies (I^2^=98.4%; heterogeneity p\<0.001).

### Prothrombin fragment 1--2 (PF 1--2)

A total of 1047 cases were included from 9 studies, of which 694 cases were allocated to the AF group and 353 to the SR group. The mean level of PF 1--2 was 1.88 nmol/mL in the AF group and 1.35 nmol/mL in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled analysis revealed that PF 1--2 was significantly higher in the AF group than SR with WMD of 0.53 nmol/mL (95% CI: 0.33--0.73; p\<0.001, [Figure 3](#f3-medscimonitbasicres-23-97){ref-type="fig"}) using a random effect model. There was significant heterogeneity among the studies (I^2^=99.5%; heterogeneity p\<0.001)

### Antithrombin III (AT-3)

A total of 300 patients were included from 6 studies. Of them, 153 cases were allocated to the AF group and 147 cases to the SR group. The mean level of AT-III was 79.39 in AF and 53.30 in SR (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled analysis revealed that the mean level of AT-III was significantly higher in the AF group compared to the SR group with WMD of 23.90 (95% CI: 7.51--40.29; p=0.004, [Supplementary Figure 1](#s1-medscimonitbasicres-23-97){ref-type="supplementary-material"}) with significant heterogeneity (I^2^=94.2%; heterogeneity p\<0.001).

### Thrombin-antithrombin (TAT)

A total of 501 cases were included from 8 studies, of which 335 cases were allocated to the AF group and 166 to the SR group. The mean level of TAT was 10.22 ng/mL in the AF group and 4.61 ng/mL in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled analysis revealed that level of TAT was significantly higher in the AF group compared to the SR group with WMD of 5.47 ng/mL (95% CI: 1.77--9.18; p=0.004, [Supplementary Figure 2](#s2-medscimonitbasicres-23-97){ref-type="supplementary-material"}) using a random effect model. There was significant heterogeneity among the studies (I^2^=99.7%; heterogeneity p\<0.001).

Association of fibrinolytic markers with AF
-------------------------------------------

### Tissue-type plasminogen activator (t-PA)

A total of 4326 cases were included from 14 studies. Patient populations of the included studies ranged from 36 to 3212 patients. From 4326 cases, 533 were allocated to the AF group and 3793 to the SR group. Mean level of t-PA was 10.97 ng/mL in the AF group and 8.61 ng/mL in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled assessment analysis indicated that t-PA in patients with AF was significantly higher compared to those with SR with WMD of 2.13 (95% CI: 1.04--3.21; p\<0.001, [Figure 4](#f4-medscimonitbasicres-23-97){ref-type="fig"}) using a random effect model. Significant heterogeneity was observed among the studies (I^2^=98.3%; heterogeneity p\<0.001).

### Plasminogen activator inhibitor (PAI)

A total of 4267 cases were included from 15 studies, of which 540 cases were in the AF group and 3727 in the SR group. The mean level of PAI was 30.59 ng/mL in AF and 19.58 ng/mL in SR group (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled analysis revealed that the level of PAI was significantly higher in the AF group compared to the SR group with WMD of 11.44 ng/mL (95% CI: 6.83--16.05; p\<0.001, [Figure 5](#f5-medscimonitbasicres-23-97){ref-type="fig"}) with significant heterogeneity (I^2^=99.4%; heterogeneity p\<0.001).

### Fibrinopeptide-A

A total of 336 cases were included from 6 studies, whereas 148 cases were allocated to the AF group and 188 to the SR group. The mean level of fibrinopeptide-A was 7.33 ng/ml in AF and 3.18 ng/ml in SR (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled analysis showed that the level of fibrinopeptide-A was statistically higher in the AF group compared to SR with WMD of 4.13 ng/mL (95% CI: 0.67--7.60; p=0.01, [Supplementary Figure 3](#s3-medscimonitbasicres-23-97){ref-type="supplementary-material"}) with significant heterogeneity (I^2^=99.6%; heterogeneity p\<0.001).

Association of endothelial markers with AF
------------------------------------------

### von Willebrand factor (vWF)

A total of 18 057 cases were enrolled to the analysis from 32 studies, of which 2607 cases were allocated to the AF group and 15450 to the SR group. The mean level of vWF was 132.38 IU/dL in the AF group and 104.27 IU/dL in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled analysis revealed a higher level of vWF in patients with AF than in patients with SR with WMD of 27.01 (95% CI: 19.79--34.23; p\<0.001, [Figure 6](#f6-medscimonitbasicres-23-97){ref-type="fig"}) using a random effect model. There was significant heterogeneity among the studies (I^2^=98.7%; heterogeneity p\<0.001).

### Soluble thrombomodulin (sTM)

A total of 591 cases were included from 7 studies. From all cases, 351 were allocated to the AF group and 240 to the SR group. The mean level of sTM was 25.96 ng/mL in the AF group and 22.04 ng/mL in the SR group (details in [Tables 1](#t1-medscimonitbasicres-23-97){ref-type="table"} and [2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Pooled analysis indicated that sTM was significantly higher in the AF group compared to the SR group with WMD of 3.92 (95% CI: 0.53--7.32; p\<0.001, [Supplementary Figure 4](#s4-medscimonitbasicres-23-97){ref-type="supplementary-material"}) using a random effect model. There was significant heterogeneity among the studies (I^2^=91.2%; heterogeneity p\<0.001).

Related clinical adverse events of AF
-------------------------------------

### Association of coagulation, fibrinolytic, and endothelial markers with thromboembolic events

Six studies reported the association of markers with thromboembolic events ([Table 3](#t3-medscimonitbasicres-23-97){ref-type="table"}). D-dimer, fibrinogen, and PF 1--2 levels were investigated in at least 2 studies and were included in the meta-analysis ([Table 2](#t2-medscimonitbasicres-23-97){ref-type="table"}). AT-III and sTM levels were reported in only 1 study and thus were not included in the analysis. Pooled analysis revealed that the level of D-dimer (number of studies=2, WMD of 60.67, 95% CI: 28.61 to 92.73; p\<0.001 and I^2^=0%; heterogeneity p=0.59, [Supplementary Figure 5](#s5-medscimonitbasicres-23-97){ref-type="supplementary-material"}) was significantly higher in patients with thromboembolic events than in patients without thromboembolic events. Pooled analysis showed that the level of fibrinogen (number of studies=3, WMD of 0.61, 95% CI: −0.30 to 1.53; p=0.19 and I^2^=92.5%; heterogeneity p\<0.001, [Supplementary Figure 6](#s6-medscimonitbasicres-23-97){ref-type="supplementary-material"}), and the level of PF1--2 (number of studies=2, WMD of 0.08, 95% CI: −0.06 to 0.22; p=0.18 and I^2^=0%; heterogeneity p=0.83, [Supplementary Figure 7](#s7-medscimonitbasicres-23-97){ref-type="supplementary-material"}) were not significantly different whether they suffered from thromboembolic events or not.

### Association of coagulation, fibrinolytic, and endothelial markers with stroke

Eight studies investigated the association of hemostatic markers with stroke ([Table 3](#t3-medscimonitbasicres-23-97){ref-type="table"}). D-dimer, fibrinogen, PF1--2, TAT, PAI, and AT-III were examined in at least 2 studies and were included in the meta-analysis ([Table 2](#t2-medscimonitbasicres-23-97){ref-type="table"}). Fibrinopeptide-A, tPA, vWF, and sTM levels were reported in only 1 study and were not included in the analysis. Pooled assessment analysis indicated that the level of PF 1--2 (number of studies=2, WMD of 1.06, 95% CI: 0.39 to 1.74; p=0.002 and I^2^=36.4%%; heterogeneity p=0.21, [Supplementary Figure 8](#s8-medscimonitbasicres-23-97){ref-type="supplementary-material"}), level of TAT (number of studies=2, WMD of 22.28, 95% CI: 4.16 to 40.39; p=0.016 and I^2^=74.5%; heterogeneity p\<0.04, [Supplementary Figure 9](#s9-medscimonitbasicres-23-97){ref-type="supplementary-material"}), and level of PAI (number of studies=2, WMD of 8.60, 95% CI: 4.12 to 13.09; p\<0.001 and I^2^=0%; P-heterogeneity=0.36, [Supplementary Figure 10](#s10-medscimonitbasicres-23-97){ref-type="supplementary-material"}) were significantly higher in patients with stoke as compared to patients without stroke. Pooled analysis showed that the levels of D-dimer (number of studies=3, WMD of 8.08, 95% CI: −32.80 to 48.96; p=0.69 and I^2^=4.7%%; heterogeneity p=0.35, [Supplementary Figure 11](#s11-medscimonitbasicres-23-97){ref-type="supplementary-material"}), fibrinogen (number of studies=6, WMD of 0.02, 95% CI: −0.22 to 0.25; p=0.88 and I^2^=79.9%%; heterogeneity p\<0.001, [Supplementary Figure 12](#s12-medscimonitbasicres-23-97){ref-type="supplementary-material"}), and AT-III (number of studies=2, WMD of 0.01, 95% CI: −0.01 to 0.03; p=0.51 and I^2^=0%%; heterogeneity p=0.39, [Supplementary Figure 13](#s13-medscimonitbasicres-23-97){ref-type="supplementary-material"}) did not significantly differ between patients with stroke and patients without stroke.

### Publication bias, subgroup analysis, and meta-regression

Begg's tests suggested that there might be publication bias for studies examining levels of D-dimer, fibrinogen, AT-III, and vWF ([Supplementary Figures 14](#s14-medscimonitbasicres-23-97){ref-type="supplementary-material"}[](#s15-medscimonitbasicres-23-97){ref-type="supplementary-material"}[](#s16-medscimonitbasicres-23-97){ref-type="supplementary-material"}[](#s17-medscimonitbasicres-23-97){ref-type="supplementary-material"}[](#s18-medscimonitbasicres-23-97){ref-type="supplementary-material"}[](#s19-medscimonitbasicres-23-97){ref-type="supplementary-material"}[](#s20-medscimonitbasicres-23-97){ref-type="supplementary-material"}[](#s21-medscimonitbasicres-23-97){ref-type="supplementary-material"}[](#s22-medscimonitbasicres-23-97){ref-type="supplementary-material"}--[23](#s23-medscimonitbasicres-23-97){ref-type="supplementary-material"}). Extra details of each study, subgroup analysis, and meta-regression are presented in [Supplementary Tables 2](#s25-medscimonitbasicres-23-97){ref-type="supplementary-material"} and [3](#s26-medscimonitbasicres-23-97){ref-type="supplementary-material"}, respectively.

Discussion
==========

For years, finding the pathophysiological mechanisms involved in AF has been an important research area in cardiology and cardiac surgery \[[@b80-medscimonitbasicres-23-97]--[@b83-medscimonitbasicres-23-97]\]. A proposed mechanism leading to an increased incidence of AF is coagulation and prothrombotic state \[[@b80-medscimonitbasicres-23-97]--[@b83-medscimonitbasicres-23-97]\]. Investigators believe that procoagulant and prothrombotic states might be more expressed in patients with chronic AF as compared to those with SR \[[@b80-medscimonitbasicres-23-97]--[@b83-medscimonitbasicres-23-97]\]. In the present study, we investigated a set of coagulation biomarkers to closely examine this possible pathophysiology of AF.

D-dimer is a byproduct of the degeneration of fibrin and reflects thrombin and fibrin turnover \[[@b84-medscimonitbasicres-23-97]\]. D-dimer is one of the surrogate markers for a hypercoagulable state which is one component of Virchow's triad \[[@b84-medscimonitbasicres-23-97]\]. The results of the present study revealed that the level of D-dimer was significantly higher in AF patients compared to those with SR. Generally, increased level of D-dimer is directly associated with an increased incidence of AF; however, it should be noted that there is a significant heterogeneity in our results. The subgroup analysis based on the year of publication, geographic area, design of the studies, age, sex, risk factors of diabetes and hypertension, number of cases, and chronic or non-chronic AF indicated that D-dimer was always considerably higher in AF groups compared with SR groups, despite heterogeneity among studies. A subgroup analysis reported that both paroxysmal and permanent AF had higher levels of D-dimer and the type of AF was not considered a factor of heterogeneity.

Fibrinogen is an acute-phase protein synthesized in the liver, and higher levels are associated with increased risk of cardiovascular diseases \[[@b85-medscimonitbasicres-23-97]\]. Our results also demonstrate that the level of fibrinogen was considerably higher in the AF group as compared to the SR group. A direct relationship between the level of fibrinogen and the incidence of AF was confirmed; however, this relationship was also associated with a justifiable heterogeneity. The analyses performed on coagulation markers PF1--2, TAT, and AT-III also indicated that the level of these markers was significantly higher in AF groups as compared to SR groups. The results of our study also showed that the type of AF could be a heterogeneity factor in the meta-analysis of D-dimer level. According to the analysis of the available data in our study, the level of D-dimer was strongly and directly related to the occurrence of thromboembolism in AF patients, while fibrinogen and PF1--2 were not. Other coagulation markers, in which no association with stroke and thromboembolism was reported, did not have sufficient data and thus no analysis was carried out.

Another proposed mechanism for the incidence of AF is fibrinolytic activity. PAI is a direct inhibitor of the plasminogen activation system, whereas its interaction with the adhesive glycoprotein plays a role in tissue remodeling \[[@b86-medscimonitbasicres-23-97]\]. Increased levels of PAI have been associated with an increased risk for coronary artery stenosis and acute coronary syndrome \[[@b86-medscimonitbasicres-23-97]\]. Our findings suggest a significant direct association between increased level of PAI and the incidence of AF, as patients with AF showed higher levels of PAI compared to those with SR.

Sorted analyses in terms of the year of publication, study design, number of cases, age, sex, diabetes, and hypertension indicated that the level of PAI in the AF group had constantly been higher than in the SR group. None of the above-mentioned criteria appeared to be a factor of heterogeneity. The results of this study predict that with the current heterogeneity in analysis on the level of PAI, history of MI and type of AF (chronic or non-chronic) could be considered factors of heterogeneity. Our results showed that the level of tPA in the AF group was considerably higher than in the SR group. There was a direct correlation between the incidence of AF and the level of tPA from laboratory and clinical studies, although statistically there was a notable heterogeneity. A subgroup analysis revealed that history of MI, type of AF, and geographical area may be considered factors of heterogeneity. Fibrinopeptide-A is also a marker of fibrinolytic activity, and we found that it was clearly higher in the AF group as compared to the SR group. However, we could not find factors of heterogeneity in the subgroup analysis. Owing to insufficient studies on alfa-2 antiplasmin, plasmin-antiplasmin, and urokinase-type plasminogen activator inhibitor, analyzing these markers was not feasible. Although based on the results, this fact is understandable and verifiable from laboratory and clinical studies, not finding a definite factor of heterogeneity of the results might be explained by the fact that other factors had affected the results of the published studies in recent years that have not been taken into account or not been reported on by their authors. Regarding the association of the level of PAI with stroke in AF patients, our results suggest a significant relationship between increased level of PAI and increased risk of stroke. Another mechanism which needs to be examined in AF patients is endothelial activity.

Increased levels of vWF have been found in inflammatory and atherosclerotic vascular diseases that are usually associated with damaged endothelium \[[@b87-medscimonitbasicres-23-97]\]. The pooled results of our study indicate that the level of vWF was significantly higher in AF patients as compared with the SR group. The results of subgroup analysis suggested that in all types of AF, including paroxysmal, persistent, and permanent, and also in terms of chronic or non-chronic AF, the level of vWF was statistically and clinically higher in the AF group. According to the subgroup analysis, geographic area, design of the studies, and number of cases could be defined as factors of heterogeneity. The findings of this study affirmed that STM, as another marker of endothelial activity, had a significant influence on the incidence of AF, as the level of STM considerably higher in AF patients compared with SR patients. Generally, increased endothelial activity appears to be associated with higher incidence of AF, which is confirmed statistically and through laboratory studies. We conducted a subgroup analysis based on cardiovascular risk factors, whereas one of the most significant cardiac risk factors affecting our results was history of MI. Also, DM, HTN, and smoking were not considered factors of heterogeneity.

Lip et al. argued that using anticoagulants could reduce the levels of D-dimer and PF1--2 in AF patients; therefore, differences in the use of anticoagulants in various studies might be considered confounding factors \[[@b68-medscimonitbasicres-23-97]\]. In this study, we defined codes for using anticoagulants. Performing a subgroup analysis, we found that on the levels of AT3, tPA, PAI, and STM, the available data about the status of using anticoagulants were confounding factors which possibly could play a part in the incidence of heterogeneity. Heterogeneity is higher in meta-analyses of non-experimental studies, which can be caused by several factors, such as: 1) many confounding factors, 2) less controlled bias, and 3) different definition of outcomes.

Meta-regression was performed on the levels of D-dimer, fibrinogen, PAI, and vWF that had greater number of studies than other markers and could be analyzed based on regression. According to the results of meta-regression on the level of D-dimer, difference in the design of studies, type of AF, and difference in geographical area of the study appeared to be factors of heterogeneity. For the level of fibrinogen, the year of publication (before or after 2000) and geographical area of the study were factors. For the level of vWF, difference in the design of studies and geographical area of the study were factors. For the level of PAI, difference in using anticoagulants was a factor.

Conclusions
===========

Generally, considering the results of this study, we can strongly claim that prothrombotic state has a critical role as a precipitating mechanism in the incidence of AF and clinical complications of thromboembolism and stroke. The levels of coagulation, fibrinolytic, and endothelial markers have been reported to be significantly higher in AF patients than in SR patients. We believe that several other interventions may affect the association of these biomarkers with the incidence of AF; however, they have not been taken into account or mentioned in the series of past and recent studies. High heterogeneity is not the end of trying to find the relation between effective markers in predicting AF, but definitely points out that in future the authors are required to converge the quality of performing studies by observing the factors of heterogeneity and other confounding factors as described in the present study. Finally, emphasizing the association of coagulation, fibrinolytic, and endothelial markers with the incidence of AF and its clinical outcomes, and defining the factors of heterogeneity using subgroup analysis and meta-regression, we believe that in meta-analysis of the relationship of the levels of biomarkers with the incidence of AF, there are real-world associations with heterogeneity. Efforts should be made to find and introduce these associations as well as factors of heterogeneity that affect the results.
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Funnel plot for publication bias of studies investigating sTM.
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Included, and excluded studies.

  Clinical outcomes and biomarkers   Studies were identified and screened \[n\]   Studies were excluded according to title, abstract or full text \[n\]   Studies were included \[n\]
  ---------------------------------- -------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------
  Fibrinogen                         315                                          275                                                                     40 approved articles with totally 58 enrolled data for meta-analysis
  D-dimer                            238                                          121                                                                     30 approved articles with totally 40 enrolled data for meta-analysis
  PF1--2                             86                                           79                                                                      7 approved articles with totally 9 enrolled data for meta-analysis
  AT-III                             98                                           94                                                                      4 approved articles with totally 6 enrolled data for meta-analysis
  TAT                                127                                          120                                                                     7 approved articles with totally 8 enrolled data for meta-analysis
  t-PA                               437                                          426                                                                     11 approved articles with totally 14 enrolled data for meta-analysis
  PAI                                91                                           80                                                                      11 approved articles with totally 15 enrolled data for meta-analysis
  Alpha-2 antiplasmin                18                                           18                                                                      --
  Fibrinopeptide-A                   21                                           18                                                                      3 approved articles with totally 4 enrolled data for meta-analysis
  u-PA                               29                                           29                                                                      --
  Plasmin-antiplasmin                22                                           21                                                                      1 approved articles with
  vWF                                185                                                                                                                  21 approved articles with totally 32 enrolled data for meta-analysis
  sTM                                37                                           31                                                                      6 approved articles with totally 7 enrolled data for meta-analysis

###### 

Extra details of characteristics of each study for exploration of heterogeneity factors.

  First Author                                                               Geographic area   Total N   Total age   Total male   Total DM   Total HTN   Total MI   Total diuretic   Total ACEI   Total. statin   Total BB   AC-code   Chronic or not   CS
  -------------------------------------------------------------------------- ----------------- --------- ----------- ------------ ---------- ----------- ---------- ---------------- ------------ --------------- ---------- --------- ---------------- ------
  Negreva \[[@b9-medscimonitbasicres-23-97]\]                                European          103       59.67       50.45        4.8        68.96       ND         ND               28.165       6.805           34.97      1         Acute            14.5
  Amdur \[[@b10-medscimonitbasicres-23-97]\]                                 North America     3762      58.9        54.55        49.8       86.7        ND         64.65            69.85        ND              56.1       4         No detection     ND
  Yusuf (disease control) \[[@b11-medscimonitbasicres-23-97]\]               Asian             65        31.5        42.85        ND         ND          ND         ND               ND           ND              ND         1         No detection     ND
  Yusuf (healthy control) \[[@b11-medscimonitbasicres-23-97]\]               Asian             65        30.055      38.55        ND         ND          ND         ND               ND           ND              ND         1         No detection     ND
  Drabik (persistent) \[[@b12-medscimonitbasicres-23-97]\]                   European          97        60.1        64.95        20         48.85       17.35      ND               52.25        53.15           60.6       4         Acute            22.5
  Drabik (PAF) \[[@b12-medscimonitbasicres-23-97]\]                          European          91        60          55.15        16.4       46.05       26.65      ND               54.05        47.45           57.25      4         Acute            20
  Borgi \[[@b13-medscimonitbasicres-23-97]\]                                 Africa            69        ND          ND           ND         ND          ND         ND               ND           ND              ND         5         No detection     ND
  Oneal (with comorbidities) \[[@b14-medscimonitbasicres-23-97]\]            North America     647       69.5        54           32.5       70          ND         ND               ND           29.5            ND         4         No detection     15
  Oneal (with comorbidities) \[[@b14-medscimonitbasicres-23-97]\]            North America     883       64.5        32.5         29.5       54.5        ND         ND               ND           30              ND         4         No detection     14
  Erdogan \[[@b15-medscimonitbasicres-23-97]\]                               European          67        69.55       49.275       10         65          ND         18               53.5         ND              43.3       3         Chronic          6
  Chen (without comorbidities) \[[@b16-medscimonitbasicres-23-97]\]          Asian             162       53.695      61.03        15         31.5        ND         ND               ND           ND              ND         4         Acute            ND
  Chen (with comorbidities) \[[@b16-medscimonitbasicres-23-97]\]             Asian             207       55.845      64.2         13.5       35.5        ND         ND               ND           ND              ND         4         Acute            ND
  Schnabel \[[@b17-medscimonitbasicres-23-97]\]                              European          4998      60.05       54.5         10.15      61.95       8.3        ND               ND           ND              ND         5         No detection     15.3
  Wei-Hong Ma \[[@b18-medscimonitbasicres-23-97]\]                           Asian             105       58          72.25        0          100         ND         ND               ND           ND              ND         2         No detection     ND
  Xu (without comorbidities) \[[@b19-medscimonitbasicres-23-97]\]            Asian             115       66.85       50.45        37.4       53.1        ND         ND               42.6         29.55           43.55      4         Chronic          38.5
  Xu (with comorbidities) \[[@b19-medscimonitbasicres-23-97]\]               Asian             115       67.975      51.3         36.5       57.5        ND         ND               40.8         26.05           40.95      4         Chronic          31.2
  Distelmaier \[[@b20-medscimonitbasicres-23-97]\]                           North America     198       73.5        61           24         60.5        25         ND               ND           ND              ND         5         Acute            ND
  Scridon (PAF) \[[@b21-medscimonitbasicres-23-97]\]                         European          69        55.5        78.5         7          39.5        ND         ND               18.5         13.5            ND         3         Acute            13
  Scridon (persistent) \[[@b21-medscimonitbasicres-23-97]\]                  European          53        55          78.5         7          35.5        ND         ND               24           15.5            ND         3         Acute            13
  Berge \[[@b22-medscimonitbasicres-23-97]\]                                 European          189       75          71           8          48          ND         19               21           34.5            28         4         No detection     ND
  Acevedo \[[@b23-medscimonitbasicres-23-97]\]                               South America     150       ND          ND           ND         ND          ND         ND               ND           ND              ND         1         No detection     ND
  Zorlu \[[@b24-medscimonitbasicres-23-97]\]                                 European          150       69.5        62           16         33          ND         ND               75.5         ND              76         1         No detection     ND
  Alonso (White) \[[@b25-medscimonitbasicres-23-97]\]                        North America     11107     55.7        52.25        12.05      34.85       6.6        ND               ND           ND              ND         1         No detection     26.7
  Alonso (African-American) \[[@b25-medscimonitbasicres-23-97]\]             North America     3751      54.8        41.2         26.05      63.65       ND         ND               ND           ND              ND         1         No detection     32
  Adamsson Eryd \[[@b26-medscimonitbasicres-23-97]\]                         European          6031      47.25       100          4.8        6           ND         ND               ND           ND                         5         No detection     48
  Fu \[[@b27-medscimonitbasicres-23-97]\]                                    Asian             169       54.45       63.5         ND         ND          ND         ND               ND           12.9            6.1        4         No detection     42.5
  Hou (disease control) \[[@b28-medscimonitbasicres-23-97]\]                 Asian             52        64.85       57.6         0          ND          ND         ND               40.35        ND              11.45      4         Acute            26.9
  Hou (healthy control) \[[@b28-medscimonitbasicres-23-97]\]                 Asian             52        65.3        57.6         0          ND          ND         ND               21.15        ND              7.65       4         Acute            26.9
  Schnabel \[[@b29-medscimonitbasicres-23-97]\]                              North America     3120      62.05       52.5         ND         38          ND         ND               ND           ND              ND         5         No detection     ND
  Letsas (PAF) \[[@b30-medscimonitbasicres-23-97]\]                          European          93        64.4        59           6          60.5        ND         ND               43           15.5            34         5         acute            ND
  Letsas (permanent) \[[@b30-medscimonitbasicres-23-97]\]                    European          89        66.6        59.5         11         63          ND         ND               52.5         13.5            35.5       5         chronic          ND
  Gartner \[[@b31-medscimonitbasicres-23-97]\]                               Australia         250       59.45       65.5         9          48.5        ND         ND               ND           ND              ND         4         No detection     ND
  Targonski (PAF and PeAF) \[[@b32-medscimonitbasicres-23-97]\]              European          56        63.5        67.7         44.75      69.6        ND         67.7             96.65        87.3            85.4       4                          12.4
  Targonski (Permanent) \[[@b32-medscimonitbasicres-23-97]\]                 European          73        69.3        66.4         33.3       72.2        ND         78.05            90.85        70.6            89.2       4                          11.3
  Marcus \[[@b33-medscimonitbasicres-23-97]\]                                North America     971       70          87.5         22.5       65.5        52         ND               57           59.5            ND         5         No detection     15
  Blann \[[@b34-medscimonitbasicres-23-97]\]                                 European          82        64.5        62.75        ND         27          ND         16.5             19           ND              18.5       3         No detection     12.6
  Topaloglu (disease control) \[[@b35-medscimonitbasicres-23-97]\]           European          46        34.5        ND           0          0           ND         ND               ND           ND              ND         5         No detection     ND
  Topaloglu (healthy control) \[[@b35-medscimonitbasicres-23-97]\]           European          38        36          ND           0          0           ND         ND               ND           ND              ND         5         No detection     ND
  Cecchi (with cerebral ischemic) \[[@b36-medscimonitbasicres-23-97]\]       European          192       73.5        60.2         7.25       45.95       ND         18.05            27.3         6.85            6.8        3         No detection     30.1
  Cecchi (without cerebral ischemic) \[[@b36-medscimonitbasicres-23-97]\]    European          224       73          59.35        6.4        47.5        ND         20.5             27.05        7.3             8.05       3         No detection     25.9
  Turgut (disease control) \[[@b37-medscimonitbasicres-23-97]\]              European          55        66.11       44.7         17.4       67.6        ND         ND               ND           ND              ND         4         No detection     ND
  Turgut (healthy control) \[[@b37-medscimonitbasicres-23-97]\]              European          46        66.56       43.95        3.85       36.55       ND         ND               ND           ND              ND         4         No detection     ND
  Heeringa \[[@b38-medscimonitbasicres-23-97]\]                              European          486       77.5        51           17.5       25          22.5       31.65            ND           ND              16.55      5         No detection     20.9
  Roldan \[[@b39-medscimonitbasicres-23-97]\]                                European          265       ND          ND           ND         ND          ND         ND               ND           ND              ND         4         No detection     ND
  Marin (acute AF) \[[@b40-medscimonitbasicres-23-97]\]                      European          48        63.5        50           0          8.3         8.3        ND               10.4         ND              8.3        4         Acute            ND
  Marin (chronic AF) \[[@b40-medscimonitbasicres-23-97]\]                    European          48        63.5        47.9         14.55      12.5        6.25       ND               6.25         ND              4.15       4         Chronic          ND
  Inoue (with comorbidities) \[[@b41-medscimonitbasicres-23-97]\]            Asian             251       ND          ND           ND         ND          ND         ND               ND           ND              ND         5         No detection     ND
  Inoue (Lone AF) \[[@b41-medscimonitbasicres-23-97]\]                       Asian             106       ND          ND           ND         ND          ND         ND               ND           ND              ND         5         No detection     ND
  Conway \[[@b42-medscimonitbasicres-23-97]\]                                European          147       68          62           7.5        26.5        13.5       ND               ND           ND              ND         3         chronic          16
  Hatzinikolaou-Kotsakou (PAF) \[[@b43-medscimonitbasicres-23-97]\]          European          35        59          77.25        8.3        13.85       13.85      ND               ND           ND              ND         5         Acute            20.5
  Hatzinikolaou-Kotsakou (persistent) \[[@b43-medscimonitbasicres-23-97]\]   European          34        60          73.5         5.85       20.585      17.6       ND               ND           ND              ND         5         Acute            20.8
  Hatzinikolaou-Kotsakou (permanent) \[[@b43-medscimonitbasicres-23-97]\]    European          37        61.5        76.15        5          22.5        15         ND               ND           ND              ND         5         Chronic          24.2
  Conway \[[@b44-medscimonitbasicres-23-97]\]                                European          74        67.5        70.2         9.45       27          1.35       ND               ND           ND              ND         5         Acute            11.2
  Kamath (PAF and PeAF) \[[@b45-medscimonitbasicres-23-97]\]                 European          62        63.5        51.6         ND         ND          ND         ND               ND           ND              ND         1         Acute            ND
  Kamath (permanent AF) \[[@b45-medscimonitbasicres-23-97]\]                 European          124       66          52.65        ND         ND          ND         ND               ND           ND              ND         1         Chronic          ND
  Marin \[[@b46-medscimonitbasicres-23-97]\]                                 European          80        70.5        55           19.5       52          6.5        ND               ND           ND              4          4         Chronic          ND
  Conway \[[@b47-medscimonitbasicres-23-97]\]                                European          486       77.5        51.05        8.3        10.595      8.6        ND               ND           ND              ND         1         No detection     10.3
  Kamath (PAF) \[[@b48-medscimonitbasicres-23-97]\]                          European          58        63          48.235       6.85       24.1        3.4        ND               ND           ND              ND         4         Acute            5.1
  Kamath (permanent AF) \[[@b48-medscimonitbasicres-23-97]\]                 European          116       65          52.25        5.15       30.45       6.85       ND               ND           ND              ND         4         Chronic          5.1
  Kamath \[[@b49-medscimonitbasicres-23-97]\]                                European          143       70          63.2         ND         ND          ND         ND               ND           ND              ND         1         No detection     5.9
  Wang \[[@b50-medscimonitbasicres-23-97]\]                                  Asian             3212      60          51.65        23.65      40.6        3.65       ND               ND           ND              ND         5         No detection     32.6
  Li-saw-Hee (PAF) \[[@b51-medscimonitbasicres-23-97]\]                      European          43        64          77.3         2.15       10.85       6.5        ND               ND           ND              ND         3         Acute            13.4
  Li-saw-Hee (PeAF) \[[@b51-medscimonitbasicres-23-97]\]                     European          43        64          77.25        2.15       13          4.3        ND               ND           ND              ND         3         Acute            11.5
  Li-saw-Hee (permanent) \[[@b51-medscimonitbasicres-23-97]\]                European          43        65          77.25        6.52       23.9        15.2       ND               ND           ND              ND         3         Chronic          11.5
  Feng \[[@b52-medscimonitbasicres-23-97]\]                                  North America     214       62.15       73.5         12.85      36          23.25      ND               ND           ND              ND         6         No detection     16.1
  Topcuoglu \[[@b53-medscimonitbasicres-23-97]\]                             European          36        62.35       61.87        13.5       42.5        ND         ND               ND           ND              ND         1         No detection     20
  Mondillo \[[@b54-medscimonitbasicres-23-97]\]                              European          80        66.95       82.85        ND         ND          ND         ND               ND           ND              ND         3         Chronic          33.7
  Giansante \[[@b55-medscimonitbasicres-23-97]\]                             European          105       63.5        55.67        8.5        29.25       ND         ND               ND           ND              ND         1         Acute            35.6
  Li-saw-Hee \[[@b56-medscimonitbasicres-23-97]\]                            European          112       67          77.5         3.85       12.5        11.55      ND               ND           ND              ND         1         Chronic          13.3
  Marin (disease control) \[[@b57-medscimonitbasicres-23-97]\]               European          42        53.5        17.35        0          ND          ND         ND               ND           ND              ND         1         No detection     ND
  Marin (healthy control) \[[@b57-medscimonitbasicres-23-97]\]               European          38        ND          ND           0          ND          ND         ND               ND           ND              ND         1         No detection     ND
  Li-saw-Hee \[[@b58-medscimonitbasicres-23-97]\]                            European          50        59          20           ND         ND          ND         ND               ND           ND              ND         5         Chronic          20
  Roldan \[[@b59-medscimonitbasicres-23-97]\]                                European          56        62          ND           0          ND          ND         ND               ND           ND              ND         1         Chronic          ND
  Tsai \[[@b50-medscimonitbasicres-23-97]\]                                  Asian             111       64          74.45        ND         ND          ND         ND               ND           ND              ND         4         Chronic          ND
  Minamino \[[@b61-medscimonitbasicres-23-97]\]                              Asian             90        63          73.3         12.5       23.5        ND         ND               ND           ND              14.5       5         Chronic          ND
  Kahn \[[@b62-medscimonitbasicres-23-97]\]                                  North America     81        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         Chronic          ND
  Sohara \[[@b63-medscimonitbasicres-23-97]\]                                Asian             30        59.1        ND           ND         ND          ND         ND               ND           ND              ND         1         Acute            ND
  Lip (PAF)\[[@b64-medscimonitbasicres-23-97]\]                              European          188       59.85       57.8         ND         ND          ND         ND               ND           ND              ND         1         Acute            30
  Lip (chronic) \[[@b64-medscimonitbasicres-23-97]\]                         European          214       61.8        56.37        ND         ND          ND         ND               ND           ND              ND         1         Chronic          33
  Lip \[[@b65-medscimonitbasicres-23-97]\]                                   European          77        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         Chronic          ND
  Mitusch \[[@b66-medscimonitbasicres-23-97]\]                               European          97        71          51.35        25         67          ND         ND               ND           ND              ND         1         No detection     ND
  Nagao \[[@b67-medscimonitbasicres-23-97]\]                                 Asian             36        79.95       44.575       ND         ND          ND         ND               ND           ND              ND         1         No detection     ND
  Lip \[[@b68-medscimonitbasicres-23-97]\]                                   European          245       61.15       53.3         ND         ND          ND         ND               ND           ND              ND         5         Chronic          ND
  Sohara \[[@b69-medscimonitbasicres-23-97]\]                                Asian             22        ND          ND           ND         ND          ND         ND               ND           ND              ND         1         Acute            ND
  Kumagai \[[@b70-medscimonitbasicres-23-97]\]                               Asian             94        62.5        48.15        ND         ND          ND         ND               ND           ND              ND         1         Chronic          ND
  Gustafsson (with stroke) \[[@b71-medscimonitbasicres-23-97]\]              European          60        77          ND           ND         ND          ND         ND               ND           ND              ND         1         No detection     30
  Gustafsson (without stroke) \[[@b71-medscimonitbasicres-23-97]\]           European          60        77          ND           ND         ND          ND         ND               ND           ND              ND         1         No detection     25

###### 

Subgroup-analysis and meta-regression.

  Subgroup                              Studies (N)                                          WMD (95% CI)               I-squared and P-value respectively   P-value of meta-regression
  ------------------------------------- ---------------------------------------------------- -------------------------- ------------------------------------ ----------------------------
  **D-dimer**                                                                                                                                                
                                                                                                                                                             
  Year of publication                                                                                                                                        0.845
   \>2000                               25                                                   243.7 (209.1 to 278.2)     99.8% and 0.001                      
   ≤2000                                16                                                   137.3 (103.6 to 171.1)     99.1% and 0.001                      
                                                                                                                                                             
  Geographic area                                                                                                                                            0.008
   Asian                                13                                                   144.4 (108.8 to 180.1)     99.7% and 0.001                      
   European                             24                                                   242.5 (199.4 to 285.7)     99% and 0.001                        
   Africa                               1                                                    0.83 (0.28 to 1.38)        --                                   
   North American                       2                                                    65.11 (−62.93 to 193.1)    98.2% and 0.001                      
   South American                       --                                                   --                         --                                   
   Australia                            1                                                    472 (429.3 to 514.6)       --                                   
                                                                                                                                                             
  Design of study                                                                                                                                            0.001
   Cohort                               35                                                   176.1 (153.7 to 198.4)     99.7% and 0.001                      
   Case-control                         6                                                    290.2 (189.5 to 390.8)     99.8% and 0.001                      
                                                                                                                                                             
  Number of population                                                                                                                                       0.49
   \>300                                2                                                    65.1 (−62.9 to 193.1)      99.9% and 0.001                      
   ≤300                                 39                                                   204.4 (179.9 to 229)       99.4% and 0.001                      
                                                                                                                                                             
  Mean Age                                                                                                                                                   0.92
   \>60 years                           26                                                   226.7 (188.6 to 264.8)     99.7% and 0.001                      
   ≤60 years                            9                                                    160.7 (77 to 244.4)        99.6% and 0.001                      
                                                                                                                                                             
  Male                                                                                                                                                       0.94
   \>70%                                3                                                    113.7 (22.2 to 205.1)      98.9% and 0.001                      
   ≤70%                                 26                                                   227.8 (187.8 to 267.8)     99.6% and 0.001                      
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          0.47
   \>30%                                2                                                    290 (271.6 to 308.4)       73.3% and 0.001                      
   ≤30%                                 20                                                   264.8 (205.7 to 323.8)     99.7% and 0.001                      
                                                                                                                                                             
  Hypertension                                                                                                                                               0.96
   \>70%                                1                                                    96.1 (47.2 to 144.7)       --                                   
   ≤70%                                 19                                                   258.6 (194.7 to 321.9)     99.8% and 0.001                      
                                                                                                                                                             
  History of myocardial infarction                                                                                                                           0.95
   \>20%                                1                                                    −0.16 (−0.42 to 0.107)     --                                   
   ≤20%                                 4                                                    761.7 (140.3 to 1383.2)    98.2% and 0.001                      
                                                                                                                                                             
  Anti-coagulant status codes                                                                                                                                0.91
   1                                    18                                                   215.3 (172 to 258.6)       98.9% and 0.001                      
   2                                    --                                                   --                         --                                   
   3                                    2                                                    154 (−110.2 to418.4)       97.6% and 0.001                      
   4                                    11                                                   331.3 (225.5 to 437.1)     99.6% and 0.001                      
   5                                    10                                                   91.1 (56 to 126.3)         99.9% and 0.001                      
   6                                    --                                                   --                         --                                   
                                                                                                                                                             
  AF                                                                                                                                                         0.015
   Chronic                              14                                                   261.3 (208.9 to 313.8)     99.6% and 0.001                      
   Non-chronic                          11                                                   104.7 (29.6 to 179.8)      99.4% and 0.001                      
                                                                                                                                                             
  Type of AF                                                                                                                                                 0.254
   Paroxysmal                           5                                                    19.6 (12.5 to 26.8)        0.0% and 0.78                        
   Persistent                           --                                                   --                         --                                   
   Permanent                            4                                                    512.5 (135.3 to 889.8)     99% and 0.001                        
                                                                                                                                                             
  Cigarette smoking                                                                                                                                          0.132
   \>30%                                7                                                    111.1 (106.1 to 116)       99.7% and 0.001                      
   ≤30%                                 8                                                    −0.136 (−0.403 to 0.131)   98.3% and 0.001                      
                                                                                                                                                             
  **Fibrinogen**                                                                                                                                             
                                                                                                                                                             
  Year of publication                                                                                                                                        0.02
   \>2000                               46                                                   0.29 (0.24 to 0.35)        96.1% and 0.001                      
   ≤2000                                12                                                   0.75 (0.54 to 0.96)        96.4% and 0.001                      
                                                                                                                                                             
  Geographic area                                                                                                                                            0.04
   Asian                                9                                                    0.35 (0.24 to 0.47)        95% and 0.001                        
   European                             40                                                   0.53 (0.38 to 0.68)        97.9% and 0.001                      
   Africa                               --                                                   --                         --                                   
   North American                       9                                                    0.10 (0.02 to 0.19)        97.3% and 0.001                      
   South American                       --                                                   --                         --                                   
   Australia                            --                                                   --                         --                                   
                                                                                                                                                             
  Design of study                                                                                                                                            0.44
   Cohort                               15                                                   0.22 (0.15 to 0.29)        98.2% and 0.001                      
   Case-control                         43                                                   0.52 (0.36 to 0.69)        97.4% and 0.001                      
                                                                                                                                                             
  Number of population                                                                                                                                       0.053
   \>300                                11                                                   0.15 (0.05 to 0.25)        98.4% and 0.001                      
   ≤300                                 47                                                   0.52 (0.39 to 0.64)        98% and 0.001                        
                                                                                                                                                             
  Mean Age                                                                                                                                                   0.94
   \>60 years                           43                                                   0.48 (0.37 to 0.59)        98.7% and 0.001                      
   ≤60 years                            13                                                   0.26 (0.17 to 0.34)        95% and 0.001                        
                                                                                                                                                             
  Male                                                                                                                                                       0.468
   \>70%                                13                                                   0.56 (0.35 to 0.77)        93.9% and 0.001                      
   ≤70%                                 37                                                   0.40 (0.31 to 0.48)        98.9% and 0.001                      
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          0.97
   \>30%                                6                                                    0.40 (0.11 to 0.69)        96.5% and 0.001                      
   ≤30%                                 37                                                   0.35 (0.28 to 0.43)        97.3% and 0.001                      
                                                                                                                                                             
  Hypertension                                                                                                                                               0.60
   \>70%                                3                                                    0.17 (0.004 to 0.35)       87.1% and 0.001                      
   ≤70%                                 40                                                   0.36 (0.29 to 0.43)        97.5% and 0.001                      
                                                                                                                                                             
  History of myocardial infarction                                                                                                                           0.58
   \>20%                                4                                                    0.01 (−0.11 to 0.13)       75.6% and 0.006                      
   ≤20%                                 16                                                   0.42 (0.26 to 0.58)        96.5% and 0.001                      
                                                                                                                                                             
  Anti-coagulant status codes                                                                                                                                0.26
   1                                    16                                                   0.45 (0.23 to 0.68)        98.5% and 0.001                      
   2                                    --                                                   --                         --                                   
   3                                    8                                                    0.62 (0.19 to 1.05)        95.3% and 0.001                      
   4                                    16                                                   0.20 (0.14 to 0.25)        92.7% and 0.001                      
   5                                    17                                                   0.53 (0.33 to 0.73)        98.6% and 0.001                      
   6                                    1                                                    0.05 (−0.13 to 0.23)       --                                   
                                                                                                                                                             
  AF                                                                                                                                                         0.23
   Chronic                              18                                                   0.7 (0.42 to 0.97)         97.6% and 0.001                      
   Non-chronic                          16                                                   0.24 (0.16 to 0.33)        92.6% and 0.001                      
                                                                                                                                                             
  Type of AF                                                                                                                                                 0.43
   Paroxysmal                           8                                                    0.38 (0.18 to 0.58)        83.9% and 0.78                       
   Persistent                           4                                                    0.42 (0.11 to 0.74)        90.2% and 0.001                      
   Permanent                            9                                                    0.54 (0.21 to 0.87)        93.6% and 0.001                      
                                                                                                                                                             
  Cigarette smoking                                                                                                                                          0.47
   \>30%                                11                                                   0.51 (0.47 TO 0.56)        98.3% and 0.001                      
   ≤30%                                 26                                                   0.09 (0.78 to 0.103)       96.5% and 0.001                      
                                                                                                                                                             
  **Prothrombotic Factor 1--2**                                                                                                                              
                                                                                                                                                             
  Year of publication                                                                                                                                        --
   \>2000                               7                                                    0.79 (−0.39 to 1.98)       98.1% and 0.001                      
   ≤2000                                2                                                    0.97 (−0.54 to 2.49)       99.8% and 0.001                      
                                                                                                                                                             
  Geographic area                                                                                                                                            --
   Asian                                3                                                    0.52 (0.23 to 0.82)        99.7% and 0.001                      
   European                             6                                                    0.47 (0.34 to 0.64)        94.8% and 0.001                      
   Africa                               --                                                   --                         --                                   
   North American                       --                                                   --                         --                                   
   South American                       --                                                   --                         --                                   
   Australia                            --                                                   --                         --                                   
                                                                                                                                                             
  Design of study                       All of them are case--control                                                                                        
   Cohort                                                                                                                                                    
   Case-control                                                                                                                                              
                                                                                                                                                             
  Number of population                                                                                                                                       --
   \>300                                1                                                    0.36 (0.33 to 0.39)        --                                   
   ≤300                                 8                                                    0.46 (0.29 to 0.62)        99.2% and 0.001                      
                                                                                                                                                             
  Mean Age                                                                                                                                                   --
   \>60 years                           6                                                    0.82 (0.26 to 1.37)        99% and 0.001                        
   ≤60 years                            --                                                   --                         --                                   
                                                                                                                                                             
  Male                                                                                                                                                       --
   \>70%                                1                                                    1.75 (1.61 to 1.88)        --                                   
   ≤70%                                 5                                                    0.58 (0.25 to 0.91)        95.5% and 0.001                      
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          --
   \>30%                                --                                                   --                         --                                   
   ≤30%                                 5                                                    0.58 (0.25 to 0.91)        95.5% and 0.001                      
                                                                                                                                                             
  Hypertension                                                                                                                                               --
   \>70%                                --                                                   --                         --                                   
   ≤70%                                 5                                                    0.38 (0.17 to 0.59)        99.7% and 0.001                      
                                                                                                                                                             
  History of myocardial infarction                                                                                                                           --
   \>20%                                --                                                   --                         --                                   
   ≤20%                                 1                                                    0.67 (0.57 to 0.76)        --                                   
                                                                                                                                                             
  Anti-coagulant status codes                                                                                                                                --
   1                                    2                                                    0.46 (−0.21 to 1.42)       72.9% and 0.05                       
   2                                    --                                                   --                         --                                   
   3                                    --                                                   --                         --                                   
   4                                    5                                                    0.84 (0.31 to 1.36)        99% and 0.001                        
   5                                    2                                                    −0.04 (−0.07 to 0.01)      77.1% and 0.03                       
   6                                    --                                                   --                         --                                   
                                                                                                                                                             
  AF                                                                                                                                                         --
   Chronic                              2                                                    1.20 (0.15 to 2.26)        99.4% and 0.001                      
   Non-chronic                          --                                                   --                         --                                   
                                                                                                                                                             
  Type of AF                                                                                                                                                 --
   Paroxysmal                           --                                                   --                         --                                   
   Persistent                           --                                                   --                         --                                   
   Permanent                            --                                                   --                         --                                   
                                                                                                                                                             
  Cigarette smoking                     No Data                                                                                                              
   \>30%                                                                                                                                                     
   ≤30%                                                                                                                                                      
                                                                                                                                                             
  **Thrombin anti thrombin**                                                                                                                                 
                                                                                                                                                             
  Year of publication                                                                                                                                        --
   \>2000                               4                                                    5.80 (−1.006 to 12.78)     99.7% and 0.001                      
   ≤2000                                4                                                    4.57 (1.77 to 7.36)        85.4% and 0.001                      
                                                                                                                                                             
  Geographic area                                                                                                                                            --
   Asian                                5                                                    6.93 (2.18 to 11.68)       98.1% and 0.001                      
   European                             2                                                    5.46 (3.43 to 7.48)        41.4% and 0.19                       
   Africa                               --                                                   --                         --                                   
   North American                       1                                                    0.05 (0.01 to 0.093)       --                                   
   South American                       --                                                   --                         --                                   
   Australia                            --                                                   --                         --                                   
                                                                                                                                                             
  Design of study                       All of them are case--control                                                                                        
   Cohort                                                                                                                                                    
   Case-control                                                                                                                                              
                                                                                                                                                             
  Number of population                  All of them are less than 300 cases                                                                                  
   \>300                                                                                                                                                     
   ≤300                                                                                                                                                      
                                                                                                                                                             
  Mean Age                                                                                                                                                   --
   \>60 years                           3                                                    5.79 (3.63 to 7.96)        37.5% and 0.202                      
   ≤60 years                            3                                                    7.89 (2.09 to 13.68)       98.8% and 0.001                      
                                                                                                                                                             
  Male                                                                                                                                                       --
   \>70%                                --                                                   --                         --                                   
   ≤70%                                 5                                                    7.87 (4.43 to 11.32)       98.3% and 0.001                      
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          --
   \>30%                                --                                                   --                         --                                   
   ≤30%                                 2                                                    5.46 (3.43 to 7.48)        41.4% and 0.191                      
                                                                                                                                                             
  Hypertension                                                                                                                                               --
   \>70%                                --                                                   --                         --                                   
   ≤70%                                 2                                                    5.46 (3.43 to 7.48)        41.4% and 0.191                      
                                                                                                                                                             
  History of myocardial infarction      No Data                                                                                                              
   \>20%                                                                                                                                                     
   ≤20%                                                                                                                                                      
                                                                                                                                                             
  Anti-coagulant status codes           All of them are Code--1                                                                                              
   1                                                                                                                                                         
   2                                                                                                                                                         
   3                                                                                                                                                         
   4                                                                                                                                                         
   5                                                                                                                                                         
   6                                                                                                                                                         
                                                                                                                                                             
  AF                                                                                                                                                         --
   Chronic                              --                                                   --                         --                                   
   Non-chronic                          2                                                    2.47 (0.55 to 4.39)        27.4% and 0.24                       
                                                                                                                                                             
  Type of AF                                                                                                                                                 --
   Paroxysmal                           5                                                    2.47 (0.55 to 4.39)        27.4% and 0.24                       
   Persistent                           --                                                   --                         --                                   
   Permanent                            --                                                   --                         --                                   
                                                                                                                                                             
  Cigarette smoking                     No sufficient data                                                                                                   
   \>30%                                                                                                                                                     
   ≤30%                                                                                                                                                      
                                                                                                                                                             
                                                                                             **Anti-thrombin III**                                           
                                                                                                                                                             
  Year of publication                                                                                                                                        --
   \>2000                               3                                                    4.26 (−8.76 to 17.28)      91% and 0.001                        
   ≤2000                                3                                                    46.78 (36.8 to 56.70)      0% and 0.833                         
                                                                                                                                                             
  Geographic area                       All of them are European                                                                                             
   Asian                                                                                                                                                     
   European                                                                                                                                                  
   Africa                                                                                                                                                    
   North American                                                                                                                                            
   South American                                                                                                                                            
   Australia                                                                                                                                                 
                                                                                                                                                             
  Design of study                       All of them are case--control                                                                                        
   Cohort                                                                                                                                                    
   Case-control                                                                                                                                              
                                                                                                                                                             
  Number of population                  All of studies have less than 300 cases                                                                              
   \>300                                                                                                                                                     
   ≤300                                                                                                                                                      
                                                                                                                                                             
  Mean Age                                                                                                                                                   --
   \>60 years                           2                                                    22.65 (−32.07 to 77.37)    94.2% and 0.001                      
   ≤60 years                            3                                                    18.96 (0.16 to 37.65)      91.1% and 0.001                      
                                                                                                                                                             
  Male                                                                                                                                                       --
   \>70%                                1                                                    −3.80 (−8.98 to 1.38)      --                                   
   ≤70%                                 1                                                    43.55 (28.29 to 58.80)     --                                   
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          --
   \>30%                                --                                                   --                         --                                   
   ≤30%                                 5                                                    30.21 (11.99 to 48.42)     91.3% and 0.001                      
                                                                                                                                                             
  Hypertension                                                                                                                                               --
   \>70%                                --                                                   --                         --                                   
   ≤70%                                 2                                                    8.65 (−6.11 to 23.43)      85.3% and 0.009                      
                                                                                                                                                             
  History of myocardial infarction      No data                                                                                                              
  \>20%                                                                                                                                                      
  ≤20%                                                                                                                                                       
                                                                                                                                                             
  Anti-coagulant status codes                                                                                                                                --
   1                                    3                                                    46.78 (36.85 to 56.70)     0.0% and 0.833                       
   2                                    --                                                   --                         --                                   
   3                                    1                                                    −3.80 (−8.98 to 1.38)      --                                   
   4                                    --                                                   --                         --                                   
   5                                    2                                                    8.65 (−6.11 to 23.43)      85.3% and 0.009                      
   6                                    --                                                   --                         --                                   
                                                                                                                                                             
  AF                                                                                                                                                         --
   Chronic                              2                                                    22.65 (−32.07 to 77.37)    94.2% and 0.001                      
   Non-chronic                          --                                                   --                         --                                   
                                                                                                                                                             
  Type of AF                                                                                                                                                 --
   Paroxysmal                           --                                                   19.6 (12.5 to 26.8)        --                                   
   Persistent                           --                                                   --                         --                                   
   Permanent                            1                                                    −3.80 (−8.98 to 1.38)      --                                   
                                                                                                                                                             
  Cigarette smoking                     No sufficient data                                                                                                   
   \>30%                                                                                                                                                     
   ≤30%                                                                                                                                                      
                                                                                                                                                             
                                                                                             **Fibrinopeptide-A**                                            
                                                                                                                                                             
  Year of publication                                                                                                                                        --
   \>2000                               1                                                    10.05 (9.37 to 10.72)      --                                   
   ≤2000                                3                                                    2.17 (−0.72 to 5.07)       99.4% and 0.001                      
                                                                                                                                                             
  Geographic area                                                                                                                                            --
   Asian                                1                                                    4.60 (4.28 o 4.91)         --                                   
   European                             3                                                    3.98 (−1.33 to 9.30)       99.7% and 0.001                      
   Africa                               --                                                   --                         --                                   
   North American                       --                                                   --                         --                                   
   South American                       --                                                   --                         --                                   
   Australia                            --                                                   --                         --                                   
                                                                                                                                                             
  Design of study                       All of studies are case--control                                                                                     
   Cohort                                                                                                                                                    
   Case-control                                                                                                                                              
                                                                                                                                                             
  Number of population                  All of studies have less than 300 cases                                                                              
   \>300                                                                                                                                                     
   ≤300                                                                                                                                                      
                                                                                                                                                             
  Mean Age                              All of studies have total age higher than 60 years                                                                   
   \>60 years                                                                                                                                                
   ≤60 years                                                                                                                                                 
                                                                                                                                                             
  Male                                                                                                                                                       --
   \>70%                                1                                                    4.60 (4.28 o 4.91)         --                                   
   ≤70%                                 1                                                    10.05 (9.37 to 10.72)      --                                   
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          --
   \>30%                                --                                                   --                         --                                   
   ≤30%                                 1                                                    10.05 (9.37 to 10.72)      --                                   
                                                                                                                                                             
  Hypertension                                                                                                                                               --
   \>70%                                --                                                   --                         --                                   
   ≤70%                                 1                                                    10.05 (9.37 to 10.72)      --                                   
                                                                                                                                                             
  History of myocardial infarction      No data                                                                                                              
   \>20%                                                                                                                                                     
   ≤20%                                                                                                                                                      
                                                                                                                                                             
  Anti-coagulant status codes                                                                                                                                --
   1                                    3                                                    3.98 (−1.33 to 9.30)       99.7% and 0.001                      
   2                                    --                                                   --                         --                                   
   3                                    --                                                   --                         --                                   
   4                                    1                                                    4.60 (4.28 to 4.97)        --                                   
   5                                    --                                                   --                         --                                   
   6                                    --                                                   --                         --                                   
                                                                                                                                                             
  AF                                                                                                                                                         --
   Chronic                              1                                                    4.60 (4.28 to 4.97)        --                                   
   Non-chronic                          1                                                    10.05 (9.37 to 10.72)      --                                   
                                                                                                                                                             
  Type of AF                                                                                                                                                 --
   Paroxysmal                           1                                                    10.05 (9.37 to 10.72)--    --                                   
   Persistent                           --                                                   --                         --                                   
   Permanent                            --                                                   --                         --                                   
                                                                                                                                                             
  Cigarette smoking                                                                                                                                          --
   \>30%                                2                                                    5.19 (4.78 to 5.63)        99.7% and 0.001                      
   ≤30%                                 1                                                    0.42 (0.11 to 0.72)        --                                   
                                                                                                                                                             
  **Tissue plasminogen activator**                                                                                                                           
                                                                                                                                                             
  Year of publication                                                                                                                                        --
   \>2000                               9                                                    3.095 (1.52 to 4.66)       95.5% and 0.001                      
   ≤2000                                5                                                    0.709 (−0.908 to 2.32)     99.2% and 0.001                      
                                                                                                                                                             
  Geographic area                                                                                                                                            --
   Asian                                2                                                    3.78 (3.30 to 4.26)        0.0% and 0.86                        
   European                             11                                                   1.86 (0.69 to 3.03)        98.4% and 0.001                      
   Africa                               --                                                   --                         --                                   
   North American                       1                                                    1.30 (0.013 to 2.58)       --                                   
   South American                       --                                                   --                         --                                   
   Australia                            --                                                   --                         --                                   
                                                                                                                                                             
  Design of study                                                                                                                                            --
   Cohort                               2                                                    1.89 (−1.82 to 5.62)       98.2% and 0.001                      
   Case-control                         12                                                   2.16 (0.98 to 3.34)        98.2% and 0.001                      
                                                                                                                                                             
  Number of population                                                                                                                                       --
   \>300                                1                                                    3.80 (3.30 to 4.29)        --                                   
   ≤300                                 13                                                   1.95 (0.88 to 3.02)        98.1% and 0.001                      
                                                                                                                                                             
  Mean Age                                                                                                                                                   --
   \>60 years                           10                                                   2.69 (1.56 to 3.83)        96.1% and 0.001                      
   ≤60 years                            3                                                    1.29 (−1.14 to 3.74)       88.8% and 0.001                      
                                                                                                                                                             
  Male                                                                                                                                                       --
   \>70%                                4                                                    3.67 (0.40 to 6.94)        96.3% and 0.001                      
   ≤70%                                 6                                                    2.34 (0.56 to 4.13)        99.2% and 0.001                      
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          --
   \>30%                                --                                                   --                         --                                   
   ≤30%                                 13                                                   1.60 (0.52 to 2.68)        98.3% and 0.001                      
                                                                                                                                                             
  Hypertension                                                                                                                                               --
   \>70%                                --                                                   --                         --                                   
   ≤70%                                 10                                                   2.41 (1.47 to 3.51)        93.5% and 0.001                      
                                                                                                                                                             
  History of myocardial infarction                                                                                                                           --
   \>20%                                2                                                    1.98 (0.81 to 3.14)        53.3% and 0.143                      
   ≤20%                                 2                                                    3.68 (3.26 to 4.10)        0.0% and 0.396                       
                                                                                                                                                             
  Anti-coagulant status codes                                                                                                                                --
   1                                    5                                                    0.21 (−1.50 to 1.93)       99.1% and 0.001                      
   2                                    --                                                   --                         --                                   
   3                                    1                                                    10.57 (8.055 to 13.085)    --                                   
   4                                    3                                                    1.94 (−0.36 to 4.26)       96.8% and 0.001                      
   5                                    4                                                    3.48 (2.76 to 4.19)        22.6% and 0.275                      
   6                                    1                                                    1.30 (0.013 to 2.58)       --                                   
                                                                                                                                                             
  AF                                                                                                                                                         --
   Chronic                              3                                                    4.43 (−1.25 to 10.12)      97.6% and 0.001                      
   Non-chronic                          2                                                    2.99 (2.11 to 3.87)        51% and 0.154                        
                                                                                                                                                             
  Type of AF                                                                                                                                                 --
   Paroxysmal                           1                                                    2.50 (1.53 to 3.46)        --                                   
   Persistent                           1                                                    3.40 (2.62 to 4.17)        --                                   
   Permanent                            1                                                    10.57 (8.055 to 13.085)    --                                   
                                                                                                                                                             
  Cigarette smoking                                                                                                                                          --
   \>30%                                2                                                    4.05 (3.56 to 4.56)        96.3% and 0.001                      
   ≤30%                                 4                                                    2.73 (2.18 to 3.27)        61.6% and 0.051                      
                                                                                                                                                             
  **Plasminogen activator inhibitor**                                                                                                                        
                                                                                                                                                             
  Year of publication                                                                                                                                        0.28
   \>2000                               10                                                   6.69 (1.79 to 11.59)       99.5% and 0.001                      
   ≤2000                                5                                                    20.72 (7.68 to 33.75)      97.4% and 0.001                      
                                                                                                                                                             
  Geographic area                                                                                                                                            0.30
   Asian                                4                                                    15.82 (0.49 to 31.14)      99.5% and 0.001                      
   European                             10                                                   10.07 (6.93 to 13.21)      98.4% and 0.001                      
   Africa                               --                                                   --                         --                                   
   North American                       1                                                    1.009 (−3.05 to 5.07)      --                                   
   South American                       --                                                   --                         --                                   
   Australia                            --                                                   --                         --                                   
                                                                                                                                                             
  Design of study                                                                                                                                            0.97
   Cohort                               1                                                    4.490 (2.71 to 7.08)       --                                   
   Case-control                         14                                                   11.28 (6.70 to 15.86)      99.4% and 0.001                      
                                                                                                                                                             
  Number of population                                                                                                                                       0.98
   \>300                                1                                                    4.490 (2.71 to 7.08)       --                                   
   ≤300                                 14                                                   11.28 (6.70 to 15.86)      99.4% and 0.001                      
                                                                                                                                                             
  Mean Age                                                                                                                                                   0.96
   \>60 years                           9                                                    6.99 (4.31 to 9.67)        91.7% and 0.001                      
   ≤60 years                            5                                                    10.36 (2.19 to 18.52)      99.8% and 0.001                      
                                                                                                                                                             
  Male                                                                                                                                                       0.18
   \>70%                                1                                                    36.42 (32.41 to 40.42)     --                                   
   ≤70%                                 8                                                    11.28 (3.14 to 19.42)      99.5% and 0.001                      
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          --
   \>30%                                --                                                   --                         --                                   
   ≤30%                                 12                                                   8.93 (6.03 to 11.88)       98.1% and 0.001                      
                                                                                                                                                             
  Hypertension                                                                                                                                               --
   \>70%                                --                                                   --                         --                                   
   ≤70%                                 9                                                    3.34 (1.30 to 5.39)        96% and 0.001                        
                                                                                                                                                             
  History of myocardial infarction                                                                                                                           0.97
   \>20%                                2                                                    1.55 (−3.66 to 6.78)       84.5% and 0.011                      
   ≤20%                                 2                                                    4.16 (3.29 to 5.03)        0.0% and 0.474                       
                                                                                                                                                             
  Anti-coagulant status codes                                                                                                                                0.014
   1                                    7                                                    21.28 (11.09 to 31.47)     98.9% and 0.001                      
   2                                    --                                                   --                         --                                   
   3                                    1                                                    4.20 (1.09 to 7.31)        --                                   
   4                                    2                                                    3.95 (3.27 to 4.64)        0.0% and 0.831                       
   5                                    4                                                    1.08 (−0.357 to 2.534)     87.1% and 0.001                      
   6                                    1                                                    −1.50 (−5.53 to 2.53)      --                                   
                                                                                                                                                             
  AF                                                                                                                                                         0.97
   Chronic                              3                                                    16.58 (−1.97 to 35.14)     95.6% and 0.001                      
   Non-chronic                          2                                                    3.80 (3.16 to 4.44)        0.0% and 0.448                       
                                                                                                                                                             
  Type of AF                                                                                                                                                 0.26
   Paroxysmal                           1                                                    3.88 (2.87 to 4.88)        --                                   
   Persistent                           1                                                    4.03 (3.08 to 4.97)        --                                   
   Permanent                            1                                                    5.90 (3.49 to 8.31)        --                                   
                                                                                                                                                             
  Cigarette smoking                                                                                                                                          0.95
   \>30%                                2                                                    5.35 (3.73 to 6.97)        0.0% and 0.568                       
   ≤30%                                 4                                                    3.80 (3.13 to 4.48)        56.9% and 0.07                       
                                                                                                                                                             
  **von Willebrand Factor**                                                                                                                                  
                                                                                                                                                             
  Year of publication                                                                                                                                        0.98
   \>2000                               28                                                   27.50 (19.43 to 35.56)     96.3% and 0.001                      
   ≤2000                                4                                                    23.67 (9.80 to 37.53)      99.5% and 0.001                      
                                                                                                                                                             
  Geographic area                                                                                                                                            0.01
   Asian                                4                                                    15.19 (7.19 to 23.19)      15.4% and 0.315                      
   European                             25                                                   30.91 (22.26 to 39.56)     99% and 0.001                        
   Africa                               --                                                   --                         --                                   
   North American                       3                                                    13.23 (10.42 to 16.04)     0.0% and 0.423                       
   South American                       --                                                   --                         --                                   
   Australia                            --                                                   --                         --                                   
                                                                                                                                                             
  Design of study                                                                                                                                            0.05
   Cohort                               5                                                    11.70 (6.62 to 16.78)      66.4% and 0.018                      
   Case-control                         27                                                   29.97 (21.49 to 38.44)     98.9% and 0.001                      
                                                                                                                                                             
  Number of population                                                                                                                                       0.10
   \>300                                4                                                    10.32 (5.54 to 15.09)      63.8% and 0.041                      
   ≤300                                 28                                                   29.78 (21.48 to 38.08)     98.8% and 0.001                      
                                                                                                                                                             
  Mean Age                                                                                                                                                   0.703
   \>60 years                           22                                                   27.88 (18.70 to 37.07)     99.1% and 0.001                      
   ≤60 years                            10                                                   23.95 (16.11 to 31.79)     85.4% and 0.001                      
                                                                                                                                                             
  Male                                                                                                                                                       0.44
   \>70%                                13                                                   27.82 (18.23 to 37.41)     87.9% and 0.001                      
   ≤70%                                 15                                                   28.74 (17.73 to 39.74)     98% and 0.001                        
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          --
   \>30%                                --                                                   --                         --                                   
   ≤30%                                 25                                                   25.34 (16.93 to 33.76)     95.6% and 0.001                      
                                                                                                                                                             
  Hypertension                                                                                                                                               0.48
   \>70%                                2                                                    16.95 (−1.44 to 35.35)     57% and 0.127                        
   ≤70%                                 24                                                   27.42 (18.17 to 36.13)     96.7% and 0.001                      
                                                                                                                                                             
  History of myocardial infarction                                                                                                                           0.97
   \>20%                                3                                                    20.98 (−14.49 to 0.56.4)   98.7% and 0.001                      
   ≤20%                                 14                                                   26.61 (14.62 to 38.60)     97.2% and 0.001                      
                                                                                                                                                             
  Anti-coagulant status codes                                                                                                                                0.81
   1                                    6                                                    9.66 (5.59 to 13.74)       93.5% and 0.001                      
   2                                    1                                                    25 (11.14 to 38.85)        --                                   
   3                                    8                                                    33.09 (18.72 to 47.47)     90.9% and 0.001                      
   4                                    7                                                    34.96 (24.55 to 45.38)     92.4% and 0.001                      
   5                                    9                                                    30.16 (13.83 to 46.49)     95.9% and 0.001                      
   6                                    1                                                    5.0 (−9.75 to 19.75)       --                                   
                                                                                                                                                             
  AF                                                                                                                                                         0.65
   Chronic                              8                                                    43 (29.03 to 56.97)        93% and 0.001                        
   Non-chronic                          12                                                   26.73 (16.88 to 36.58)     94.7% and 0.001                      
                                                                                                                                                             
  Type of AF                                                                                                                                                 0.75
   Paroxysmal                           4                                                    29.17 (7.99 to 50.34)      96.5% and 0.001                      
   Persistent                           5                                                    25.02 (6.51 to 43.52)      96.1% and 0.001                      
   Permanent                            4                                                    43.01 (10.43 to 75.59)     95.6% and 0.001                      
                                                                                                                                                             
  Cigarette smoking                                                                                                                                          0.98
   \>30%                                4                                                    3.53 (2.48 to 4.58)        95.8% and 0.001                      
   ≤30%                                 21                                                   14.60 (13.67 to 15.53)     98.7% and 0.001                      
                                                                                                                                                             
  **Soluble thrombomodulin**                                                                                                                                 
                                                                                                                                                             
  Year of Publication                                                                                                                                        --
   \>2000                               6                                                    4.36 (2.79 to 5.93)        86.8% and 0.001                      
   ≤2000                                1                                                    −13.0 (−19.12 to −6.87)    --                                   
                                                                                                                                                             
  Geographic area                                                                                                                                            --
   Asian                                --                                                   --                         --                                   
   European                             6                                                    3.81 (0.35 to 7.27)        92.6% and 0.001                      
   Africa                               --                                                   --                         --                                   
   North American                       --                                                   --                         --                                   
   South American                       1                                                    1.81 (1.03 to 2.58)        --                                   
   Australia                            --                                                   --                         --                                   
                                                                                                                                                             
  Design of study                                                                                                                                            --
   Cohort                               1                                                    2.02 (1.88 to 2.15)        --                                   
   Case-control                         6                                                    3.87 (0.31 to 7.43)        90.6% and 0.001                      
                                                                                                                                                             
  Number of population                  All of studies have less than 300 cases                                                                              
   \>300                                                                                                                                                     
   ≤300                                                                                                                                                      
                                                                                                                                                             
  Mean Age                                                                                                                                                   --
   \>60 years                           4                                                    6.04 (2.88 to 9.21)        89.5% and 0.001                      
   ≤60 years                            2                                                    −5.16 (−19.87 to 9.54)     95.7% and 0.001                      
                                                                                                                                                             
  Male                                                                                                                                                       --
   \>70%                                2                                                    6.84 (0.02 to 13.65)       86.8% and 0.001                      
   ≤70%                                 4                                                    1.68 (−2.13 to 5.50)       94.3% and 0.001                      
                                                                                                                                                             
  Diabetes mellitus                                                                                                                                          --
   \>30%                                --                                                   --                         --                                   
   ≤30%                                 4                                                    5.10 (2.03 to 8.17)        91.2% and 0.001                      
                                                                                                                                                             
  Hypertension                                                                                                                                               --
   \>70%                                --                                                   --                         --                                   
   ≤70%                                 4                                                    5.10 (2.03 to 8.17)        91.2% and 0.001                      
                                                                                                                                                             
  History of myocardial infarction                                                                                                                           --
   \>20%                                --                                                   --                         --                                   
   ≤20%                                 3                                                    6.18 (4.78 to 7.58)        0.0% and 0.794                       
                                                                                                                                                             
  Anti-coagulant status codes                                                                                                                                --
   1                                    3                                                    4.36 (−0.52 to 9.25)       56.9% and 0.09                       
   2                                    --                                                   --                         --                                   
   3                                    1                                                    12.28 (6.09 to 18.46)      --                                   
   4                                    2                                                    6.02 (4.61 to 7.50)        0.0% and 0.839                       
   5                                    1                                                    −5.27 (−19.76 to 9.21)     --                                   
   6                                    --                                                   --                         --                                   
                                                                                                                                                             
  AF                                                                                                                                                         --
   Chronic                              4                                                    3.38 (−5.27 to 12.04)      92.6% and 0.001                      
   Non-chronic                          2                                                    2.85 (1.52 to 4.17)        88.7% and 0.001                      
                                                                                                                                                             
  Type of AF                                                                                                                                                 --
   Paroxysmal                           1                                                    2.02 (1.88 to 2.15)        --                                   
   Persistent                           --                                                   --                         --                                   
   Permanent                            1                                                    12.28 (6.09 to 18.46)      --                                   
                                                                                                                                                             
  Cigarette smoking                                                                                                                                          --
   \>30%                                1                                                    12.28 (6.09 to 18.46)      --                                   
   ≤30%                                 3                                                    2.01 (1.88 to 2.14)        56.3% and 0.101                      
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###### 

Characteristics of included studies for meta-analysis of association of biomarkers and AF.

  First Author                                                               Year   Country    Design         N-AF   N-SR    Age-AF   Age-SR   Male-AF   Male-SR   AC-AF   AC-SR   Type of AF                NOS
  -------------------------------------------------------------------------- ------ ---------- -------------- ------ ------- -------- -------- --------- --------- ------- ------- ------------------------- -----
  Negreva \[[@b9-medscimonitbasicres-23-97]\]                                2016   Bulgaria   Cohort         51     52      59.84    59.5     50.9      50        0       0       Paroxysmal                6
  Amdur \[[@b10-medscimonitbasicres-23-97]\]                                 2016   USA        Cohort         642    3120    60.8     57       53.8      55.3      48.6    42      ND                        9
  Yusuf (disease control) \[[@b11-medscimonitbasicres-23-97]\]               2015   India      Case-Control   35     30      31.86    31.14    45.7      40        0       0       ND                        8
  Yusuf (healthy control) \[[@b11-medscimonitbasicres-23-97]\]               2015   India      Case-control   35     30      28.97    31.14    37.1      40        0       0       ND                        8
  Drabik (persistent) \[[@b12-medscimonitbasicres-23-97]\]                   2015   Poland     Case-control   47     50      60.8     59.4     65.9      64        38.3    26      Persistent                8
  Drabik (PAF) \[[@b12-medscimonitbasicres-23-97]\]                          2015   Poland     Case-control   41     50      60.6     59.4     46.3      64        51.2    26      Paroxysmal                8
  Borgi \[[@b13-medscimonitbasicres-23-97]\]                                 2015   Tunis      Case-control   50     19      61.8     ND       42        ND        ND      ND      Combined                  7
  Oneal (with comorbidities) \[[@b14-medscimonitbasicres-23-97]\]            2015   USA        Cohort         79     568     71       68       44        64        47      42      ND                        9
  Oneal (with comorbidities) \[[@b14-medscimonitbasicres-23-97]\]            2015   USA        Cohort         63     820     65       64       22        43        58      38      ND                        9
  Erdogan \[[@b15-medscimonitbasicres-23-97]\]                               2014   Turkey     Case-control   34     33      70.5     68.6     47.05     51.5      66.6    0       Permanent                 9
  Chen (without comorbidities) \[[@b16-medscimonitbasicres-23-97]\]          2014   China      Cohort         62     100     55.1     52.29    58.06     64        19      12      Combined                  8
  Chen (with comorbidities) \[[@b16-medscimonitbasicres-23-97]\]             2014   China      Cohort         107    100     59.4     52.29    64.4      64        26      12      Combined                  8
  Schnabel \[[@b17-medscimonitbasicres-23-97]\]                              2014   Germany    Cohort         161    4837    64.9     55.2     59        50        ND      ND      ND                        9
  Wei-Hong Ma \[[@b18-medscimonitbasicres-23-97]\]                           2014   China      Cohort         55     50      59       57       74.5      70        100     100     ND                        8
  Xu (without comorbidities) \[[@b19-medscimonitbasicres-23-97]\]            2014   China      Cohort         57     58      65.9     67.8     50.9      50        50.9    15.5    ND                        7
  Xu (with comorbidities) \[[@b19-medscimonitbasicres-23-97]\]               2014   China      Cohort         57     58      68.95    67       52.6      50        49.1    15.5    ND                        7
  Distelmaier \[[@b20-medscimonitbasicres-23-97]\]                           2014   USA        Case-control   66     132     73.5     73.5     61        61        ND      ND      ND                        7
  Scridon (PAF) \[[@b21-medscimonitbasicres-23-97]\]                         2013   France     Case-control   52     17      56       55       81        76        100     0       Paroxysmal                7
  Scridon (persistent) \[[@b21-medscimonitbasicres-23-97]\]                  2013   France     Case-control   36     17      55       55       81        76        100     0       Persistent                7
  Berge \[[@b22-medscimonitbasicres-23-97]\]                                 2013   Norway     Cohort         63     126     75       75       71.4      70.6      8       33      Combined                  9
  Acevedo \[[@b23-medscimonitbasicres-23-97]\]                               2012   Chile      Case-control   130    20      67       ND       ND        ND        0       0       Combined                  8
  Zorlu \[[@b24-medscimonitbasicres-23-97]\]                                 2012   Turkey     Cohort         31     119     72       67       64        60        0       0       ND                        8
  Alonso (White) \[[@b25-medscimonitbasicres-23-97]\]                        2012   USA        Cohort         976    10131   57.3     54.1     58.4      46.1      0       0       ND                        9
  Alonso (African-American) \[[@b25-medscimonitbasicres-23-97]\]             2012   USA        Cohort         233    3518    56.2     53.4     44.6      37.8      0       0       ND                        9
  Adamsson Eryd \[[@b26-medscimonitbasicres-23-97]\]                         2011   Sweden     Cohort         667    5364    47.8     46.7     100       100       ND      ND      ND                        9
  Fu \[[@b27-medscimonitbasicres-23-97]\]                                    2011   China      Case-control   90     79      54.1     54.8     70        57        22      0       Combined                  8
  Hou (disease control) \[[@b28-medscimonitbasicres-23-97]\]                 2010   China      Case-control   26     26      65.2     64.5     57.6      57.6      7.6     11.5    ND                        8
  Hou (healthy control) \[[@b28-medscimonitbasicres-23-97]\]                 2010   China      Case-control   26     26      65.2     65.4     57.6      57.6      7.6     0       ND                        8
  Schnabel \[[@b29-medscimonitbasicres-23-97]\]                              2010   USA        Cohort         209    2911    66.3     57.8     60        45        ND      ND      ND                        9
  Letsas (PAF) \[[@b30-medscimonitbasicres-23-97]\]                          2010   Greece     Case-control   45     48      67.5     61.3     62        56        ND      ND      Paroxysmal                9
  Letsas (permanent) \[[@b30-medscimonitbasicres-23-97]\]                    2010   Greece     Case-control   41     48      71.9     61.3     63        56        ND      ND      Permanent                 9
  Gartner \[[@b31-medscimonitbasicres-23-97]\]                               2008   Austria    Case-control   222    28      64.5     54.4     63        68        55      40      ND                        6
  Targonski (PAF and PeAF) \[[@b32-medscimonitbasicres-23-97]\]              2008   Poland     Case-control   26     30      70.3     56.7     65.4      70        84.6    83.3    Combined (PAF and PeAF)   8
  Targonski (Permanent) \[[@b32-medscimonitbasicres-23-97]\]                 2008   Poland     Case-control   43     30      69.9     68.7     62.8      70        48.8    83.3    Permanent                 8
  Marcus \[[@b33-medscimonitbasicres-23-97]\]                                2008   USA        Case-control   46     925     74       66       94        81        ND      ND      ND                        9
  Blann \[[@b34-medscimonitbasicres-23-97]\]                                 2007   UK         Case-control   54     28      65       64       64.8      60.7      60      0       ND                        6
  Topaloglu (disease control) \[[@b35-medscimonitbasicres-23-97]\]           2007   Turkey     Case-control   18     28      37       32       ND        ND        ND      ND      ND                        6
  Topaloglu (healthy control) \[[@b35-medscimonitbasicres-23-97]\]           2007   Turkey     Case-control   18     20      37       35       ND        ND        ND      ND      ND                        6
  Cecchi (with cerebral ischemic) \[[@b36-medscimonitbasicres-23-97]\]       2006   Italy      Case-control   62     130     75       72       61.2      59.2      100     0       ND                        6
  Cecchi (without cerebral ischemic) \[[@b36-medscimonitbasicres-23-97]\]    2006   Italy      Case-control   94     130     74       72       59.5      59.2      100     0       ND                        6
  Turgut (disease control) \[[@b37-medscimonitbasicres-23-97]\]              2006   Turkey     Case-control   26     29      67.42    64.8     30.8      58.6      38.5    20.7    ND                        8
  Turgut (healthy control) \[[@b37-medscimonitbasicres-23-97]\]              2006   Turkey     Case-control   26     20      67.42    65.7     30.8      57.1      38.5    0       ND                        8
  Heeringa \[[@b38-medscimonitbasicres-23-97]\]                              2006   UK         Cohort         162    324     78       77       51        51        ND      ND      ND                        8
  Roldan \[[@b39-medscimonitbasicres-23-97]\]                                2005   Spain      Case-control   191    74      72       ND       51.3      ND        100     62.2    ND                        7
  Marin (acute AF) \[[@b40-medscimonitbasicres-23-97]\]                      2004   Spain      Case-control   24     24      64       63       50        50        16.6    0       ND                        8
  Marin (chronic AF) \[[@b40-medscimonitbasicres-23-97]\]                    2004   Spain      Case-control   24     24      64       63       45.8      50        41.6    0       ND                        8
  Inoue (with comorbidities) \[[@b41-medscimonitbasicres-23-97]\]            2004   Japan      Case-control   159    92      ND       ND       ND        ND        ND      ND      ND                        7
  Inoue (Lone AF) \[[@b41-medscimonitbasicres-23-97]\]                       2004   Japan      Case-control   87     19      ND       ND       ND        ND        ND      ND      ND                        7
  Conway \[[@b42-medscimonitbasicres-23-97]\]                                2004   UK         Case-control   106    41      69       67       63        61        86      0       Permanent                 6
  Hatzinikolaou-Kotsakou (PAF) \[[@b43-medscimonitbasicres-23-97]\]          2004   Greece     Case-control   18     17      59       59       72.2      82.3      ND      ND      Paroxysmal                8
  Hatzinikolaou-Kotsakou (persistent) \[[@b43-medscimonitbasicres-23-97]\]   2004   Greece     Case-control   17     17      61       59       64.7      82.3      ND      ND      Persistent                8
  Hatzinikolaou-Kotsakou (permanent) \[[@b43-medscimonitbasicres-23-97]\]    2004   Greece     Case-control   20     17      64       59       70        82.3      ND      ND      Permanent                 8
  Conway \[[@b44-medscimonitbasicres-23-97]\]                                2004   UK         Case-control   37     37      67       68       72.9      67.5      ND      ND      Persistent                6
  Kamath (PAF and PeAF) \[[@b45-medscimonitbasicres-23-97]\]                 2003   UK         Case-control   31     31      61       66       61.3      41.9      0       0       Combined (PAF and PeAF)   6
  Kamath (permanent AF) \[[@b45-medscimonitbasicres-23-97]\]                 2003   UK         Case-control   93     31      66       66       63.4      41.9      0       0       Permanent                 6
  Marin \[[@b46-medscimonitbasicres-23-97]\]                                 2003   Spain      Case-control   48     32      71       70       63        47        38      9       ND                        7
  Conway \[[@b47-medscimonitbasicres-23-97]\]                                2003   UK         Cohort         162    324     78       77       51.2      50.9      0       0       ND                        8
  Kamath (PAF) \[[@b48-medscimonitbasicres-23-97]\]                          2002   UK         Case-control   29     29      61       65       55.17     41.3      37.9    0       Paroxysmal                7
  Kamath (permanent AF) \[[@b48-medscimonitbasicres-23-97]\]                 2002   UK         Case-control   87     29      65       65       63.2      41.3      37.9    0       Permanent                 7
  Kamath \[[@b49-medscimonitbasicres-23-97]\]                                2002   UK         Case-control   93     50      70       70       62.4      64        0       0       ND                        6
  Wang \[[@b50-medscimonitbasicres-23-97]\]                                  2002   Taiwan     Cohort         53     3159    66.1     53.9     56.6      46.7      ND      ND      ND                        9
  Li-saw-Hee (PAF) \[[@b51-medscimonitbasicres-23-97]\]                      2001   UK         Case-control   23     20      65       63       69.6      85        69.6    0       Paroxysmal                8
  Li-saw-Hee (PeAF) \[[@b51-medscimonitbasicres-23-97]\]                     2001   UK         Case-control   23     20      65       63       69.5      85        100     0       Persistent                8
  Li-saw-Hee (permanent) \[[@b51-medscimonitbasicres-23-97]\]                2001   UK         Case-control   23     20      67       63       69.5      85        100     0       Permanent                 8
  Feng \[[@b52-medscimonitbasicres-23-97]\]                                  2001   USA        Case-control   47     167     62       62.3     74.5      72.5      76.6    ND      ND                        8
  Topcuoglu \[[@b53-medscimonitbasicres-23-97]\]                             2000   Turkey     Case-control   15     21      61.9     62.8     66.6      57.14     0       0       ND                        6
  Mondillo \[[@b54-medscimonitbasicres-23-97]\]                              2000   Italy      Case-control   45     35      67.6     66.3     80        85.7      55      0       Permanent                 7
  Giansante \[[@b55-medscimonitbasicres-23-97]\]                             2000   Italy      Case-control   35     70      64       63       54.2      57.14     0       0       Paroxysmal                7
  Li-saw-Hee \[[@b56-medscimonitbasicres-23-97]\]                            2000   UK         Case-control   52     60      68       66       80        75        0       0       ND                        6
  Marin (disease control) \[[@b57-medscimonitbasicres-23-97]\]               1999   Spain      Case-control   18     24      56       51       22.2      12.5      0       0       ND                        6
  Marin (healthy control) \[[@b57-medscimonitbasicres-23-97]\]               1999   Spain      Case-control   18     20      56       ND       22.2      ND        0       0       ND                        6
  Li-saw-Hee \[[@b58-medscimonitbasicres-23-97]\]                            1999   UK         Case-control   25     25      60       58       20        20        ND      ND      ND                        6
  Roldan \[[@b59-medscimonitbasicres-23-97]\]                                1998   Spain      Case-control   36     20      62       62       62        ND        0       0       ND                        7
  Tsai \[[@b50-medscimonitbasicres-23-97]\]                                  1998   Taiwan     Case-control   73     38      65       63       75.3      73.6      11      0       ND                        6
  Minamino \[[@b61-medscimonitbasicres-23-97]\]                              1997   Japan      Case-control   45     45      63       63       73.3      73.3      ND      ND      ND                        6
  Kahn \[[@b62-medscimonitbasicres-23-97]\]                                  1997   Canada     Case-control   50     31      ND       65       ND        38.7      0       0       ND                        7
  Sohara \[[@b63-medscimonitbasicres-23-97]\]                                1997   Japan      Case-control   21     9       59.1     59.1     71.4      ND        0       0       Paroxysmal                6
  Lip (PAF) \[[@b64-medscimonitbasicres-23-97]\]                             1996   UK         Case-control   30     158     60.8     58.9     60        55.6      0       0       Paroxysmal                8
  Lip (chronic) \[[@b64-medscimonitbasicres-23-97]\]                         1996   UK         Case-control   56     158     64.7     58.9     57.14     55.6      0       0       ND                        8
  Lip \[[@b65-medscimonitbasicres-23-97]\]                                   1996   UK         Case-control   51     26      70.4     ND       ND        ND        0       0       ND                        6
  Mitusch \[[@b66-medscimonitbasicres-23-97]\]                               1996   Germany    Case-control   69     28      72       70       42        60.7      0       0       ND                        7
  Nagao \[[@b67-medscimonitbasicres-23-97]\]                                 1995   Japan      Case-control   17     19      81.5     78.4     47.05     42.1      0       0       ND                        8
  Lip \[[@b68-medscimonitbasicres-23-97]\]                                   1995   UK         Case-control   87     158     63       59.3     50.6      56        ND      ND      ND                        7
  Sohara \[[@b69-medscimonitbasicres-23-97]\]                                1994   Japan      Case-control   13     9       60       ND       76.9      ND        0       0       Paroxysmal                6
  Kumagai \[[@b70-medscimonitbasicres-23-97]\]                               1990   Japan      Case-control   73     21      64       61       53.4      42.9      0       0       ND                        7
  Gustafsson (with stroke) \[[@b71-medscimonitbasicres-23-97]\]              1990   Sweden     case-control   20     40      77       77       ND        ND        0       0       ND                        8
  Gustafsson (without stroke) \[[@b71-medscimonitbasicres-23-97]\]           1990   Sweden     case-control   20     40      77       77       ND        ND        0       0       ND                        8

###### 

Information about markers and these levels in each study.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                                                               Markers                                                         Levels
  -------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------
  **Occurrence of AF**                                                                                                                       

  Negreva \[[@b9-medscimonitbasicres-23-97]\]                                sTM                                                             sTM: AF: 6.5±0.4 *vs.* SR: 4.48±0.28

  Amdur \[[@b10-medscimonitbasicres-23-97]\]                                 Fibrinogen                                                      Fibrinogen: AF: 4.3±1.1 *vs.* SR: 4.1±1.2

  Yusuf (disease control) \[[@b11-medscimonitbasicres-23-97]\]               TAT and PAI                                                     TAT: AF: 22.65±2.35 *vs.* SR: 9.07±1.22\
                                                                                                                                             PAI: AF: 47.9±2.5 *vs.* SR: 13.52±3.57

  Yusuf (healthy control) \[[@b11-medscimonitbasicres-23-97]\]               TAT and PAI                                                     TAT: AF: 15.37±1.87 *vs.* SR: 9.07±1.22\
                                                                                                                                             PAI: AF: 26.72±3.37 *vs.* SR: 13.52±3.57

  Drabik (persistent) \[[@b12-medscimonitbasicres-23-97]\]                   Fibrinogen, tPA, PAI, and vWF                                   Fibrinogen: AF: 3.32±0.27 *vs.* SR: 3.12±0.32\
                                                                                                                                             tPA: AF: 12.8±1.8 *vs.* SR: 9.4±2.1\
                                                                                                                                             PAI: AF: 28.1±1.35 *vs.* SR: 24.07±3.12\
                                                                                                                                             vWF: AF: 171±8 *vs.* SR: 121.75±5.25

  Drabik (PAF) \[[@b12-medscimonitbasicres-23-97]\]                          Fibrinogen, tPA, PAI, and vWF                                   Fibrinogen: AF: 3.25±0.25 *vs.* SR: 3.12±0.32\
                                                                                                                                             tPA: AF: 11.9±2.5 *vs.* SR: 9.4±2.1\
                                                                                                                                             PAI: AF: 27.95±1.65 *vs.* SR: 24.07±3.12\
                                                                                                                                             vWF: AF: 172.75±10.75 *vs.* SR: 121.75±5.25

  Borgi \[[@b13-medscimonitbasicres-23-97]\]                                 D-dimer                                                         D-dimer: AF: 590±506 *vs.* SR: 225.26±112.95

  Oneal (with comorbidities) \[[@b14-medscimonitbasicres-23-97]\]            Fibrinogen                                                      Fibrinogen: AF: 0.42±0.10 *vs.* SR: 0.41±0.11

  Oneal (with comorbidities) \[[@b14-medscimonitbasicres-23-97]\]            Fibrinogen                                                      Fibrinogen: AF: 0.41±0.07 *vs.* SR: 0.38±0.10

  Erdogan \[[@b15-medscimonitbasicres-23-97]\]                               D-dimer and Fibrinogen                                          D-dimer: AF: 204.7±159.2 *vs.* SR: 186.2±105.6\
                                                                                                                                             Fibrinogen: AF: 2.74±0.63 *vs.* SR: 2.27±0.51

  Chen (without comorbidities) \[[@b16-medscimonitbasicres-23-97]\]          D-dimer and Fibrinogen                                          D-dimer: AF: 660±60 *vs.* SR: 270±20\
                                                                                                                                             Fibrinogen: AF: 2.63±0.07 *vs.* SR: 2.57±0.12

  Chen (with comorbidities) \[[@b16-medscimonitbasicres-23-97]\]             D-dimer and Fibrinogen                                          D-dimer: AF: 350±20 *vs.* SR: 270±20\
                                                                                                                                             Fibrinogen: AF: 2.62±0.05 *vs.* SR: 2.57±0.12

  Schnabel \[[@b17-medscimonitbasicres-23-97]\]                              Fibrinogen                                                      Fibrinogen: AF: 4.11±0.35 *vs.* SR: 3.47±0.23

  Wei-Hong Ma \[[@b18-medscimonitbasicres-23-97]\]                           vWF                                                             vWF: AF: 166±46 *vs.* SR: 141±24

  Xu (without comorbidities) \[[@b19-medscimonitbasicres-23-97]\]            D-dimer and Fibrinogen                                          D-dimer: AF: 379.5±48 *vs.* SR: 98.5±5\
                                                                                                                                             Fibrinogen: AF: 3.64±0.89 *vs.* SR: 2.62±0.5

  Xu (with comorbidities) \[[@b19-medscimonitbasicres-23-97]\]               D-dimer and Fibrinogen                                          D-dimer: AF: 398.25±54.75 *vs.* SR: 98.5±5\
                                                                                                                                             Fibrinogen: AF: 3.68±0.62 *vs.* SR: 2.62±0.5

  Distelmaier \[[@b20-medscimonitbasicres-23-97]\]                           Fibrinogen                                                      Fibrinogen: AF: 4±0.27 *vs.* SR: 4.11±0.23

  Scridon (PAF) \[[@b21-medscimonitbasicres-23-97]\]                         vWF                                                             vWF: AF: 107.5±9.4 *vs.* SR: 86.8±14

  Scridon (persistent) \[[@b21-medscimonitbasicres-23-97]\]                  vWF                                                             vWF: AF: 125.2±10.4 *vs.* SR: 86.8±14

  Berge \[[@b22-medscimonitbasicres-23-97]\]                                 tPA                                                             tPA: AF: 15.2±1.8 *vs.* SR: 15.2±1

  Acevedo \[[@b23-medscimonitbasicres-23-97]\]                               TAT and sTM                                                     TAT: AF: 0.054±0.23 *vs.* SR: 0.002±0.003\
                                                                                                                                             sTM: AF: 52.2±111 *vs.* 44±13

  Zorlu \[[@b24-medscimonitbasicres-23-97]\]                                 D-dimer                                                         D-dimer: AF: 1351.75±497.75 *vs.* SR: 644.25±113.8

  Alonso (White) \[[@b25-medscimonitbasicres-23-97]\]                        Fibrinogen and vWF                                              Fibrinogen: AF: 3.19±0.64 *vs.* SR: 2.95±0.61\
                                                                                                                                             vWF: AF: 124.5±46.4 *vs.* SR: 111.3±42.6

  Alonso (African-American) \[[@b25-medscimonitbasicres-23-97]\]             Fibrinogen and vWF                                              Fibrinogen: AF: 3.32±0.76 *vs.* SR: 3.18±0.71\
                                                                                                                                             vWF: AF: 148.9±67.5 *vs.* SR: 132.4±55.6

  Adamsson Eryd \[[@b26-medscimonitbasicres-23-97]\]                         Fibrinogen                                                      Fibrinogen: AF: 3.6±0.8 *vs.* SR: 3.5±0.8

  Fu \[[@b27-medscimonitbasicres-23-97]\]                                    Fibrinogen and vWF                                              Fibrinogen: AF: 3.3±0.9 *vs.* SR: 3±0.6\
                                                                                                                                             vWF: AF: 116.5±37.4 *vs.* SR: 105.6±29.8

  Hou (disease control) \[[@b28-medscimonitbasicres-23-97]\]                 D-dimer and vWF                                                 D-dimer: AF: 327±96 *vs.* SR: 231±83\
                                                                                                                                             vWF: AF: 132±38 *vs.* SR: 126±36

  Hou (healthy control) \[[@b28-medscimonitbasicres-23-97]\]                 D-dimer and vWF                                                 D-dimer: AF: 327±96 *vs.* SR: 208±80\
                                                                                                                                             vWF: AF: 132±38 *vs.* SR: 113±37

  Schnabel \[[@b29-medscimonitbasicres-23-97]\]                              D-dimer and Fibrinogen                                          D-dimer: AF: 451.5±56 *vs.* SR: 321±43.6\
                                                                                                                                             Fibrinogen: AF: 3.52±0.15 *vs.* SR: 3.31±0.15

  Letsas (PAF) \[[@b30-medscimonitbasicres-23-97]\]                          Fibrinogen                                                      Fibrinogen: AF: 3.74±1.03 *vs.* SR: 3.6±0.89

  Letsas (permanent) \[[@b30-medscimonitbasicres-23-97]\]                    Fibrinogen                                                      Fibrinogen: AF: 4.12±0.99 *vs.* SR: 3.6±0.89

  Gartner \[[@b31-medscimonitbasicres-23-97]\]                               D-dimer                                                         D-dimer: AF: 929.3±105.1 *vs.* SR: 457.3±108.8

  Targonski (PAF and PeAF) \[[@b32-medscimonitbasicres-23-97]\]              Fibrinogen                                                      Fibrinogen: AF: 3.39±0.67 *vs.* SR: 3.6±0.76

  Targonski (Permanent) \[[@b32-medscimonitbasicres-23-97]\]                 Fibrinogen                                                      Fibrinogen: AF: 3.91±0.77 *vs.* SR: 3.6±0.76

  Marcus \[[@b33-medscimonitbasicres-23-97]\]                                D-dimer                                                         D-dimer: AF: 392±91 *vs.* SR: 408±72

  Blann \[[@b34-medscimonitbasicres-23-97]\]                                 vWF                                                             vWF: AF: 180±86 *vs.* SR: 109±62

  Topaloglu (disease control) \[[@b35-medscimonitbasicres-23-97]\]           D-dimer, Fibrinogen, AT-III, tPA, PAI and vWF                   D-dimer: AF: 384±130 *vs.* SR: 372±160\
                                                                                                                                             Fibrinogen: AF: 2.89±0.71 *vs.* SR: 2.82±0.37\
                                                                                                                                             AT-III: AF: 98.6±11.1 *vs.* SR: 97.9±21.2\
                                                                                                                                             tPA: AF: 8.89±3.5 *vs.* SR: 5.82±1.79\
                                                                                                                                             PAI: AF: 1.05±0.97 *vs.* SR: 1.16±0.7\
                                                                                                                                             vWF: AF: 134.9±68 *vs.* SR: 115.7±53.4

  Topaloglu (healthy control) \[[@b35-medscimonitbasicres-23-97]\]           D-dimer, Fibrinogen, AT-III, tPA, PAI and vWF                   D-dimer: AF: 384±130 *vs.* SR: 19±8.3\
                                                                                                                                             Fibrinogen: AF: 2.89±0.71 *vs.* SR: 2.3±0.47\
                                                                                                                                             AT-III: AF: 98.6±11.1 *vs.* SR: 82.8±8.6\
                                                                                                                                             tPA: AF: 8.89±3.5 *vs.* SR: 7.3±3.7\
                                                                                                                                             PAI: AF: 1.05±0.97 *vs.* SR: 1.24±0.65\
                                                                                                                                             vWF: AF: 134.9±68 *vs.* SR: 75.1±17

  Cecchi (with cerebral ischemic) \[[@b36-medscimonitbasicres-23-97]\]       Fibrinogen                                                      Fibrinogen: AF: 3.68±1.04 *vs.* SR: 3.07±0.3

  Cecchi (without cerebral ischemic) \[[@b36-medscimonitbasicres-23-97]\]    Fibrinogen                                                      Fibrinogen: AF: 4.36±1.22 *vs.* SR: 3.07±0.3

  Turgut (disease control) \[[@b37-medscimonitbasicres-23-97]\]              Fibrinogen and PF1--2                                           Fibrinogen: AF: 3.64±0.86 *vs.* SR: 3.47±1.1\
                                                                                                                                             PF1--2: AF: 2.83±0.89 *vs.* SR: 2.33±0.8

  Turgut (healthy control) \[[@b37-medscimonitbasicres-23-97]\]              Fibrinogen and PF1--2                                           Fibrinogen: AF: 3.64±0.86 *vs.* SR: 2.51±0.61\
                                                                                                                                             PF1--2: AF: 2.83±0.89 *vs.* SR: 1.94±0.64

  Heeringa \[[@b38-medscimonitbasicres-23-97]\]                              Fibrinogen and vWF                                              Fibrinogen: AF: 2.32±0.7 *vs.* SR: 2.32±0.9\
                                                                                                                                             vWF: AF: 144±32 *vs.* SR: 138±40.2

  Roldan \[[@b39-medscimonitbasicres-23-97]\]                                PF1--2                                                          PF1--2: AF: 1.41±0.15 *vs.* SR: 1.05±0.09

  Marin (acute AF) \[[@b40-medscimonitbasicres-23-97]\]                      D-dimer, vWF and sTM                                            D-dimer: AF: 2350±2680 *vs.* SR: 390±280\
                                                                                                                                             vWF: AF: 137±36.9 *vs.* SR: 86.7±33.2\
                                                                                                                                             sTM: AF: 12.1±4.1 *vs.* 5.9±2.7

  Marin (chronic AF) \[[@b40-medscimonitbasicres-23-97]\]                    D-dimer, vWF and sTM                                            D-dimer: AF: 1120±650 *vs.* SR: 390±280\
                                                                                                                                             vWF: AF: 133.1±25 *vs.* SR: 86.7±33.2\
                                                                                                                                             sTM: AF: 11.8±4.6 *vs.* 5.9±2.7

  Inoue (with comorbidities) \[[@b41-medscimonitbasicres-23-97]\]            D-dimer and PF1--2                                              D-dimer: AF: 158.6±9.2 *vs.* SR: 79.1±10.3\
                                                                                                                                             PF1--2: AF: 0.98±0.05 *vs.* SR: 1.04±0.04

  Inoue (Lone AF) \[[@b41-medscimonitbasicres-23-97]\]                       D-dimer and PF1--2                                              D-dimer: AF: 92.1±6.7 *vs.* SR: 31±7.4\
                                                                                                                                             PF1--2: AF: 0.79±0.06 *vs.* SR: 0.82±0.05

  Conway \[[@b42-medscimonitbasicres-23-97]\]                                Fibrinogen and vWF                                              Fibrinogen: AF: 2.65±0.17 *vs.* SR: 2.72±0.28\
                                                                                                                                             vWF: AF: 132±26 *vs.* SR: 125±21

  Hatzinikolaou-Kotsakou (PAF) \[[@b43-medscimonitbasicres-23-97]\]          Fibrinogen and vWF                                              Fibrinogen: AF: 3.3±0.9 *vs.* SR: 2.4±0.8\
                                                                                                                                             vWF: AF: 119±0.9 *vs.* SR: 104±22

  Hatzinikolaou-Kotsakou (persistent) \[[@b43-medscimonitbasicres-23-97]\]   Fibrinogen and vWF                                              Fibrinogen: AF: 3.8±0.4 *vs.* SR: 2.4±0.8\
                                                                                                                                             vWF: AF: 129±19 *vs.* SR: 104±22

  Hatzinikolaou-Kotsakou (permanent) \[[@b43-medscimonitbasicres-23-97]\]    Fibrinogen and vWF                                              Fibrinogen: AF: 4.5±0.6 *vs.* SR: 2.4±0.8\
                                                                                                                                             vWF: AF: 158±15 *vs.* SR: 104±22

  Conway \[[@b44-medscimonitbasicres-23-97]\]                                Fibrinogen and vWF                                              Fibrinogen: AF: 2.83±0.25 *vs.* SR: 2.67±0.27\
                                                                                                                                             vWF: AF: 130±25 *vs.* SR: 126±21

  Kamath (PAF and PeAF) \[[@b45-medscimonitbasicres-23-97]\]                 D-dimer and Fibrinogen                                          D-dimer: AF: 760±195 *vs.* SR: 637.5±202.5\
                                                                                                                                             Fibrinogen: AF: 2.9±0.7 *vs.* SR: 2.6±0.4

  Kamath (permanent AF) \[[@b45-medscimonitbasicres-23-97]\]                 D-dimer and Fibrinogen                                          D-dimer: AF: 1497.5±368.3 *vs.* SR: 637.5±202.5\
                                                                                                                                             Fibrinogen: AF: 2.7±0.6 *vs.* SR: 2.6±0.4

  Marin \[[@b46-medscimonitbasicres-23-97]\]                                 PF1--2                                                          PF1--2: AF: 1.61±0.31 *vs.* SR: 0.94±0.1

  Conway \[[@b47-medscimonitbasicres-23-97]\]                                Fibrinogen and vWF                                              Fibrinogen: AF: 0.8±0.29 *vs.* SR: 0.79±0.3\
                                                                                                                                             vWF: AF: 144±32 *vs.* SR: 138±32

  Kamath (PAF) \[[@b48-medscimonitbasicres-23-97]\]                          D-dimer and Fibrinogen                                          D-dimer: AF: 675.75±151.75 *vs.* SR: 659.5±185.5\
                                                                                                                                             Fibrinogen: AF: 2.9±0.7 *vs.* SR: 2.6±0.5

  Kamath (permanent AF) \[[@b48-medscimonitbasicres-23-97]\]                 D-dimer and Fibrinogen                                          D-dimer: AF: 1552.5±398.3 *vs.* SR: 659.5±185.5\
                                                                                                                                             Fibrinogen: AF: 2.7±0.6 *vs.* SR: 2.6±0.5

  Kamath \[[@b49-medscimonitbasicres-23-97]\]                                D-dimer and Fibrinogen                                          D-dimer: AF: 1085±176.6 *vs.* SR: 724.25±240.75\
                                                                                                                                             Fibrinogen: AF: 2.8±0.7 *vs.* SR: 2.6±0.4

  Wang \[[@b50-medscimonitbasicres-23-97]\]                                  Fibrinogen, tPA and PAI                                         Fibrinogen: AF: 3.15±0.76 *vs.* SR: 3.03±0.63\
                                                                                                                                             tPA: AF: 12.05±1.85 *vs.* SR: 8.25±0.96\
                                                                                                                                             PAI: AF: 23.95±8.1 *vs.* SR: 19.05±4.1

  Li-saw-Hee (PAF) \[[@b51-medscimonitbasicres-23-97]\]                      Fibrinogen and vWF                                              Fibrinogen: AF: 3.3±0.7 *vs.* SR: 2.5±0.6\
                                                                                                                                             vWF: AF: 130±34 *vs.* SR: 101±30

  Li-saw-Hee (PeAF) \[[@b51-medscimonitbasicres-23-97]\]                     Fibrinogen and vWF                                              Fibrinogen: AF: 2.7±0.8 *vs.* SR: 2.5±0.6\
                                                                                                                                             vWF: AF: 106±26 *vs.* SR: 101±30

  Li-saw-Hee (permanent) \[[@b51-medscimonitbasicres-23-97]\]                Fibrinogen and vWF                                              Fibrinogen: AF: 3.1±0.9 *vs.* SR: 2.5±0.6\
                                                                                                                                             vWF: AF: 143±47 *vs.* SR: 101±30

  Feng \[[@b52-medscimonitbasicres-23-97]\]                                  Fibrinogen, tPA, PAI and vWF                                    Fibrinogen: AF: 3.33±0.53 *vs.* SR: 3.28±0.65\
                                                                                                                                             tPA: AF: 11.8±4 *vs.* SR: 10.5±3.9\
                                                                                                                                             PAI: AF: 24.2±10.7 *vs.* SR: 25.7±17.3\
                                                                                                                                             vWF: AF: 142±46.2 *vs.* SR: 137±43.4

  Topcuoglu \[[@b53-medscimonitbasicres-23-97]\]                             PF1--2, TAT, tPA and PAI                                        PF1--2: AF: 2.29±1.25 *vs.* SR: 1.37±0.87\
                                                                                                                                             TAT: AF: 10.07±6.04 *vs.* SR: 6.59±5.12\
                                                                                                                                             tPA: AF: 23.93±10.17 *vs.* SR: 21.16±12.72\
                                                                                                                                             PAI: AF: 37.05±22.32 *vs.* SR: 31.36±21.5

  Mondillo \[[@b54-medscimonitbasicres-23-97]\]                              D-dimer, Fibrinogen, AT-III, tPA, PAI, vWF and sTM              D-dimer: AF: 458.5±175 *vs.* SR: 170.25±23.75\
                                                                                                                                             Fibrinogen: AF: 3.81±1.09 *vs.* SR: 2.68±0.8\
                                                                                                                                             AT-III: AF: 99.9±15.8 *vs.* SR: 103.7±7.1\
                                                                                                                                             tPA: AF: 20.37±7.8 *vs.* SR: 9.8±3.21\
                                                                                                                                             PAI: AF: 15.2±6.2 *vs.* SR: 9.3±4.8\
                                                                                                                                             vWF: AF: 164.04±43.8 *vs.* SR: 93.44±33.04\
                                                                                                                                             sTM: AF: 39.14±13.2 *vs.* SR: 26.86±14.6

  Giansante \[[@b55-medscimonitbasicres-23-97]\]                             D-dimer and Fibrinopeptide-A                                    D-dimer: AF: 347±54 *vs.* SR: 323.75±46.75\
                                                                                                                                             Fibrinopeptide-A: AF: 12.9±2 *vs.* SR: 2.85±0.57

  Li-saw-Hee \[[@b56-medscimonitbasicres-23-97]\]                            Fibrinogen, vWF and sTM                                         Fibrinogen: AF: 2.9±0.9 *vs.* SR: 2.6±0.8\
                                                                                                                                             vWF: AF: 137±27 *vs.* SR: 103±33\
                                                                                                                                             sTM: AF: 52±17 *vs.* SR: 44±13

  Marin (disease control) \[[@b57-medscimonitbasicres-23-97]\]               D-dimer, AT-III, tPA and PAI                                    D-dimer: AF: 533±111.25 *vs.* SR: 542.02±147.4\
                                                                                                                                             AT-III: AF: 58.4±32.75 *vs.* SR: 14.85±4.8\
                                                                                                                                             tPA: AF: 1.94±0.34 *vs.* SR: 2.34±0.14\
                                                                                                                                             PAI: AF: 43.77±8.62 *vs.* SR: 31.37±9.3

  Marin (healthy control) \[[@b57-medscimonitbasicres-23-97]\]               D-dimer, AT-III, tPA and PAI                                    D-dimer: AF: 533±111.25 *vs.* SR: 15.92±6.07\
                                                                                                                                             AT-III: AF: 58.4±32.75 *vs.* SR: 10.25±1.1\
                                                                                                                                             tPA: AF: 1.94±0.34 *vs.* SR: 3.01±0.8\
                                                                                                                                             PAI: AF: 43.77±8.62 *vs.* SR: 7.35±0.9

  Li-saw-Hee \[[@b58-medscimonitbasicres-23-97]\]                            D-dimer, Fibrinogen, vWF and sTM                                D-dimer: AF: 54±26 *vs.* SR: 32±20\
                                                                                                                                             Fibrinogen: AF: 4.2±0.6 *vs.* SR: 3.1±0.6\
                                                                                                                                             vWF: AF: 149±24 *vs.* SR: 103±30\
                                                                                                                                             sTM: AF: 27±10 *vs.* SR: 40±12

  Roldan \[[@b59-medscimonitbasicres-23-97]\]                                D-dimer, Fibrinogen, AT-III, tPA, PAI and Plasmin-antiplasmin   D-dimer: AF: 549.38±311.16 *vs.* SR: 12.3±3.7\
                                                                                                                                             Fibrinogen: AF: 3.69±0.81 *vs.* SR: 3.11±0.6\
                                                                                                                                             AT-III: AF: 62.47±79.46 *vs.* SR: 10.35±2.9\
                                                                                                                                             tPA: AF: 2.31±0.9 *vs.* SR: 2.88±1.58\
                                                                                                                                             PAI: AF: 42.78±22.85 *vs.* SR: 8.8±5.04\
                                                                                                                                             Plasmin-antiplasmin: AF: 275.31±151.69 *vs.* SR: 232.5±65.7

  Tsai \[[@b50-medscimonitbasicres-23-97]\]                                  PF1--2 and Fibrinopeptide-A                                     PF1--2: AF: 4.74±0.49 *vs.* SR: 2.99±0.24\
                                                                                                                                             Fibrinopeptide-A: AF: 6±1.3 *vs.* SR: 1.4±0.3

  Minamino \[[@b61-medscimonitbasicres-23-97]\]                              D-dimer, Fibrinogen, tPA and PAI                                D-dimer: AF: 160±55 *vs.* SR: 90±21\
                                                                                                                                             Fibrinogen: AF: 2.55±0.9 *vs.* SR: 1.93±0.71\
                                                                                                                                             tPA: AF: 12.05±5.4 *vs.* SR: 8.4±1.85\
                                                                                                                                             PAI: AF: 62.12±33.07 *vs.* SR: 52±17.4

  Kahn \[[@b62-medscimonitbasicres-23-97]\]                                  Fibrinogen                                                      Fibrinogen: AF: 3.7±0.8 *vs.* SR: 3.2±1.1

  Sohara \[[@b63-medscimonitbasicres-23-97]\]                                D-dimer, Fibrinogen and TAT                                     D-dimer: AF: 141.7±208.6 *vs.* SR: 67.2±31.6\
                                                                                                                                             Fibrinogen: AF: 2.62±0.65 *vs.* SR: 2.25±0.37\
                                                                                                                                             TAT: AF: 6.68±5.11 *vs.* SR: 3.11±1.86

  Lip (PAF) \[[@b64-medscimonitbasicres-23-97]\]                             D-dimer and Fibrinogen                                          D-dimer: AF: 96.75±21.75 *vs.* SR: 77.5±8.33\
                                                                                                                                             Fibrinogen: AF: 3.15±0.24 *vs.* SR: 2.6±0.19

  Lip (chronic) \[[@b64-medscimonitbasicres-23-97]\]                         D-dimer and Fibrinogen                                          D-dimer: AF: 149.5±37.5 *vs.* SR: 77.5±8.33\
                                                                                                                                             Fibrinogen: AF: 3.82±0.28 *vs.* SR: 2.6±0.19

  Lip \[[@b65-medscimonitbasicres-23-97]\]                                   D-dimer                                                         D-dimer: AF: 241.25±56.75 *vs.* SR: 103±22

  Mitusch \[[@b66-medscimonitbasicres-23-97]\]                               D-dimer, Fibrinogen, PF1--2, TAT, tPA and PAI                   D-dimer: AF: 788±76 *vs.* SR: 405±46\
                                                                                                                                             Fibrinogen: AF: 4.5±0.2 *vs.* SR: 3.1±0.3\
                                                                                                                                             PF1--2: AF: 1.2±0.1 *vs.* SR: 1±0.1\
                                                                                                                                             TAT: AF: 8.5±1.6 *vs.* SR: 2.5±0.3\
                                                                                                                                             tPA: AF: 9.6±0.5 *vs.* SR: 7.2±0.5\
                                                                                                                                             PAI: 57.9±4.3 *vs.* SR: 47.7±4.9

  Nagao \[[@b67-medscimonitbasicres-23-97]\]                                 D-dimer and TAT                                                 D-dimer: AF: 366.3±211.3 *vs.* SR: 147.2±60.9\
                                                                                                                                             TAT: AF: 13.81±14.51 *vs.* SR: 3.47±2.52

  Lip \[[@b68-medscimonitbasicres-23-97]\]                                   D-dimer, Fibrinogen and vWF                                     D-dimer: AF: 105.25±23.8 *vs.* SR: 77±8.3\
                                                                                                                                             Fibrinogen: AF: 3.71±0.28 *vs.* SR: 2.6±0.12\
                                                                                                                                             vWF: AF: 157.5±14.3 *vs.* SR: 109.25±11.16

  Sohara \[[@b69-medscimonitbasicres-23-97]\]                                D-dimer, Fibrinogen and TAT                                     D-dimer: AF: 78.6±48.2 *vs.* SR: 67.2±31.7\
                                                                                                                                             Fibrinogen: AF: 2.4±0.31 *vs.* SR: 2.25±0.3\
                                                                                                                                             TAT: AF: 4.7±3.2 *vs.* SR: 3.1±1.9

  Kumagai \[[@b70-medscimonitbasicres-23-97]\]                               D-dimer                                                         D-dimer: AF: 150±19 *vs.* SR: 61±3

  Gustafsson (with stroke) \[[@b71-medscimonitbasicres-23-97]\]              D-dimer, Fibrinogen, Fibrinopeptide-A and vWF                   D-dimer: AF: 279.4±78.12 *vs.* SR: 169.12±34.3\
                                                                                                                                             Fibrinogen: AF: 4.4±0.2 *vs.* SR: 3.82±0.22\
                                                                                                                                             Fibrinopeptide-A: AF: 5.75±1.25 *vs.* SR: 4.25±0.7\
                                                                                                                                             vWF: AF: 17.75±2.25 *vs.* SR: 14.75±1.27

  Gustafsson (without stroke) \[[@b71-medscimonitbasicres-23-97]\]           D-dimer, Fibrinogen, Fibrinopeptide-A and vWF                   D-dimer: AF: 258.25±67 *vs.* SR: 169.12±34.3\
                                                                                                                                             Fibrinogen: AF: 4.5±0.35 *vs.* SR: 3.82±0.22\
                                                                                                                                             Fibrinopeptide-A: AF: 4.67±0.5 *vs.* SR: 4.25±0.7\
                                                                                                                                             vWF: AF: 17.87±2.62 *vs.* SR: 14.75±1.27

  **Occurrence of stroke in AF patients**                                                                                                    

  Skov \[[@b72-medscimonitbasicres-23-97]\]                                  D-dimer and Fibrinogen                                          D-dimer: Stroke: 240±135 *vs.* without stroke: 250±63\
                                                                                                                                             Fibrinogen: Stroke: 3.63±0.34 *vs.* without stroke: 3.77±0.36

  Zabczyk \[[@b73-medscimonitbasicres-23-97]\]                               D-dimer, Fibrinogen, PAI and sTM                                D-dimer: Stroke: 306±164.4 *vs.* without stroke: 234±106.5\
                                                                                                                                             Fibrinogen: Stroke: 3.24±0.27 *vs.* without stroke: 3.32±0.22\
                                                                                                                                             PAI: Stroke: 28.35±7.33 *vs.* without stroke: 20.3±6.1\
                                                                                                                                             sTM: Stroke: 7.37±0.87 *vs.* without stroke: 3.27±0.32

  Cecchi \[[@b36-medscimonitbasicres-23-97]\]                                Fibrinogen                                                      Fibrinogen: Stroke: 3.68±1.04 *vs.* without stroke: 4.36±1.22

  Loffredo \[[@b74-medscimonitbasicres-23-97]\]                              Fibrinogen                                                      Fibrinogen: Stroke: 3.63±1.06 *vs.* without stroke: 3.14±0.78

  Topcuoglu \[[@b53-medscimonitbasicres-23-97]\]                             PF1--2, TAT, tPA and PAI                                        PF1--2: Stroke: 2.68±2.84 *vs.* without stroke: 2.29±1.25\
                                                                                                                                             TAT: Stroke: 43.88±44.45 *vs.* without stroke: 10.07±6.04\
                                                                                                                                             tPA: Stroke: 25.42±27.23 *vs.* without stroke: 23.93±10.17\
                                                                                                                                             PAI: Stroke: 53.39±32.91 *vs.* without stroke: 37.05±22.32

  Soncini \[[@b75-medscimonitbasicres-23-97]\]                               PF1--2 and TAT                                                  PF1--2: Stroke: 2.65±0.53 *vs.* without stroke: 1.41±0.17\
                                                                                                                                             TAT: Stroke: 26.05±9.22 *vs.* without stroke: 11.18±4.5

  Kahn \[[@b62-medscimonitbasicres-23-97]\]                                  Fibrinogen and AT-III                                           Fibrinogen: Stroke: 3.8±0.9 *vs.* without stroke: 3.7±0.8\
                                                                                                                                             AT-III: Stroke: 1±0.14 *vs.* without stroke: 1±0.13

  Gustafsson \[[@b71-medscimonitbasicres-23-97]\]                            D-dimer, Fibrinogen, AT-III, Fibrinopeptide-A and vWF           D-dimer: Stroke: 291.5±156.3 *vs.* without stroke: 275.5±134\
                                                                                                                                             Fibrinogen: Stroke: 4.4±0.2 *vs.* without stroke: 4.5±0.35\
                                                                                                                                             AT-III: Stroke: 0.92±0.04 *vs.* without stroke: 0.91±0.01\
                                                                                                                                             Fibrinopeptide-A: Stroke: 5.75±1.25 *vs.* without stroke: 4.67±0.57\
                                                                                                                                             vWF: Stroke: 17.1±2.2 *vs.* without stroke: 15.6±2.6

  **Occurrence of Thromboembolism events in AF patients**                                                                                    

  Zabczyk \[[@b73-medscimonitbasicres-23-97]\]                               D-dimer, Fibrinogen and sTM                                     D-dimer: TE: 311±134 *vs.* without TE: 234±105.5\
                                                                                                                                             Fibrinogen: TE: 3.4±0.15 *vs.* without TE: 3.35±0.25\
                                                                                                                                             sTM: TE: 6.05±1.25 *vs.* without TE: 3.20±0.35

  Roldan \[[@b76-medscimonitbasicres-23-97]\]                                PF1--2                                                          PF1--2: TE: 1.37±0.4 *vs.* without TE: 1.31±0.33

  Feinberg \[[@b77-medscimonitbasicres-23-97]\]                              PF1--2                                                          PF1--2: TE: 0.7±0.5 *vs.* without TE: 0.6±0.4

  Pongratz \[[@b78-medscimonitbasicres-23-97]\]                              Fibrinogen and AT-III                                           Fibrinogen: TE: 4.1±1.3 *vs.* without TE: 3.7±1.5\
                                                                                                                                             AT-III: TE: 99±13 *vs.* without TE: 105±22

  Black \[[@b79-medscimonitbasicres-23-97]\]                                 Fibrinogen                                                      Fibrinogen: TE: 6±1.32 *vs.* without TE: 4.56±1.64

  Kumagi \[[@b70-medscimonitbasicres-23-97]\]                                D-dimer                                                         D-dimer: TE: 196±73 *vs.* without TE: 140±19
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Characteristics of included studies for meta-analysis of association of biomarkers and clinical adverse events related to AF.

  First Author                                      Country and year   Study design   Number   Mean age   AC in patients with adverse events   AC in patients without adverse events   Adverse events                    NOS
  ------------------------------------------------- ------------------ -------------- -------- ---------- ------------------------------------ --------------------------------------- --------------------------------- -----
  Skov \[[@b72-medscimonitbasicres-23-97]\]         Denmark-2014       Case-control   179      71.6       100%                                 100%                                    Stroke                            8
  Zabczyk \[[@b73-medscimonitbasicres-23-97]\]      Poland-2011        Case-control   62       78         81.8%                                72.5%                                   Stroke and thromboembolic event   8
  Cecchi \[[@b36-medscimonitbasicres-23-97]\]       Italy-2006         Case-control   156      74.4       100%                                 100%                                    Stroke                            7
  Loffredo \[[@b74-medscimonitbasicres-23-97]\]     Italy-2005         Case-control   163      72.3       70%                                  63.4%                                   Stroke                            8
  Topcuoglu \[[@b53-medscimonitbasicres-23-97]\]    Turkey-2001        Case-control   39       63.6       --                                   --                                      Stroke                            7
  Soncini \[[@b75-medscimonitbasicres-23-97]\]      Italy-1998         Case-control   32       71.5       --                                   --                                      Stroke                            7
  Kahn \[[@b62-medscimonitbasicres-23-97]\]         Canada-1997        Case-control   75       72.7       100%                                 100%                                    Stroke                            7
  Gustafsson \[[@b71-medscimonitbasicres-23-97]\]   Sweden-1990        Case-control   40       70         --                                   --                                      Stroke                            8
  Roldan \[[@b76-medscimonitbasicres-23-97]\]       Spain-2003         Case-control   191      72.3       100%                                 100%                                    Thromboembolic event              8
  Feinberg \[[@b77-medscimonitbasicres-23-97]\]     UK-1999            Cohort         726      --         --                                   --                                      Thromboembolic event              8
  Pongratz \[[@b78-medscimonitbasicres-23-97]\]     Germany-1997       Case-control   60       65.7       --                                   --                                      Thromboembolic event              6
  Black \[[@b79-medscimonitbasicres-23-97]\]        Australia-1993     Case-control   135      --         50%                                  28%                                     Thromboembolic event              8
  Kumagi \[[@b70-medscimonitbasicres-23-97]\]       Japan-1990         Case-control   49       --         --                                   --                                      Thromboembolic event              7
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